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SUBSTITUTED ISOCOUMARINS AS SERINE 
PROTEASE INHIBITORS AND 
ANTI-INFLAMMATORY AGENTS 
2 
ity by accelerating the binding of natural plasma prote-
ase inhibitor antithrombin III with coagulation factors, 
and warfarin acts as a vitamin K antagonist and inhibits 
the synthesis of coagulation factors. None of the antico-
This is a continuation of copending application Ser. 
No. 07/516,289 filed on Apr. 30, 1990 now abandoned, 
which is a continuation-in-part of application Ser. No. 
374,980, filed on Jul. 3, 1989 now U.S. Pat. No. 
4,954,519 and application Ser. No. 215,994, filed on Jul. 
7, 1988, now abandoned. 
5 agulant drugs, antithrombotic drugs, fibrinolytic agents 
and antiplatelet drugs are highly effective in all clinical 
situations and many induce side reactions (Von Kaulla 
in Burger's Medicinal Chemistry, Part II, Wolff ed, 
1979, pp 1081-1132, incorporated herein by reference). 
BACKGROUND OF THE INVENTION 
10 Coagulation disorders such as disseminated intravascu-
lar coagulation, bleeding complications of medical and 
surgical procedures and bleeding complications of sys-
temic illness are still difficult to manage (Ingram, Bro-
1. Field of the Invention 
This invention relates to a novel class of heterocyclic 15 
compounds useful for selectively inhibiting trypsin-like 
enzymes, selectively inhibiting chymotrypsin-like en-
zymes, selectively inhibiting elastase or for generally 
inhibiting serine proteases of all classes. This invention 
also relates to a method of controlling blood coagula- 20 
tion, complement activation, fibrinolysis, tumor inva-
siveness and treating inflammation, blistering, viral in-
fection in patients using the novel compounds of the 
present invention. We have found that isocoumarins 
substituted with basic groups are potent inhibitors of 25 
blood coagulation enzymes, tryptases, plasmin, comple-
ment proteins, and cytotoxic lymphocyte granzymes 
and isocoumarins substituted with hydrophobic groups 
are potent inhibitors of chymases and elastases, there-
fore they are useful as anticoagulants, anti-inflammatory 30 
and anti-tumor agents. 
2. Description of the Related Art 
Serine proteases play critical roles in several physio-
logical processes such as digestion, blood coagulation, 
complement activation, fibrinolysis, viral infection, fer- 35 
tilization, and reproduction. Serine proteases are not 
only a physiological necessity, but also a potential ha-
zard if they are not controlled. Blood coagulation serine 
proteases are responsible for vascular clotting, cerebral 
infarction, and coronary infarction. Plasmin and plas- 40 
minogen activator are involved in tumor invasiveness, 
tissue remodeling, blistering, and clot dissociation. Un-
controlled proteolysis by elastases may cause pancreati-
tis, emphysema, rheumatoid ·arthritis, bronchial inflam-
mation and adult respiratory distress syndrome. It has 45 
been suggested that a new trypsin-like cellular enzyme 
is involved in the infection of human immunodeficiency 
virus type I (HIV-1; Hattori et al., FEBS Letters 248, 
pp 48-52 (1989)), which is a causative agent of acquired 
immunodeficiency syndrome (AIDS). Accordingly, 50 
specific and selective inhibitors of these proteases 
should be potent anticoagulants, anti-inflammatory 
agents, anti-tumor agents and anti-viral agents useful in 
the treatment of protease-related diseases (Powers and 
Harper, in Proteinase Inhibitors, Barrett and Salvesen, 55 
eds., Elsevier, 1986, pp 55-152, incorporated herein by 
reference). In vitro proteolysis by trypsin, chymotryp-
sin or the elastase family is a serious problem in the 
production, purification, isolation, transport or storage 
of peptides and proteins. 60 
Anticoagulants and antithrombotic drugs are used in 
a variety of thrombotic disorders. The 1986 Physician's 
Desk Reference lists three anticoagulant drugs (heparin, 
protamine sulfate and warfarin), one antiplatelet drug 
(aspirin) and several thrombolytic agents. Heparin and 65 
warfarin are commonly used clinically for prevention 
and treatment of venous thrombosis and pulmonary 
embolism. Heparin inhibits the blood coagulation activ-
zovic and Slater in Bleeding Disorders, Blackwell Sci-
entific Publications, 1982, pp 1-413). In the treatment of 
patients with coagulation problems, anticoagulant or 
antithrombotic agents of diverse mechanisms are ur-
gently sought in order to provide better medical care. 
Anti-inflammatory agents are used to treat elastase-
associated inflammation including rheumatoid arthritis 
and emphysema. Although the naturally occurring pro-
tease inhibitor, al-protease inhibitor (al-Pl) has been 
used to treat patients with emphysema, this inhibitor is 
not widely used clinically due to the high dosage 
needed for the treatment and difficulty of producing 
large quantities. Therefore small molecular weight elas-
tase inhibitors are needed for therapy. 
SUMMARY OF THE INVENTION 
It is an object of this invention to find a novel group 
of specific inhibitors for trypsin, elastase, chymotrypsin 
and other serine proteases of similar substrate specificity 
and for serine proteases in general. Inhibitors are com-
pounds that reduce or eliminate the catalytic activity of 
the enzyme. Trypsin and trypsin-like enzymes normally 
cleave peptide bonds in proteins and peptides where the 
amino acid residue on the carbonyl side of the split bond 
(P1 residue) is Lys or Arg. Elastase and elastase-Iike 
enzymes, on the other hand, cleave peptide bonds 
where the P1 amino acid is Ala, Val, Ser, Leu and other 
similar amino acids. Chymotrypsin and chymotrypsin-
like enzymes hydrolyze peptide bonds where P1 amino 
acid is Trp, Tyr, Phe, Met, Leu or other amino acid 
residues which contain aromatic or large alkyl side 
chains. All of the above enzymes have extensive sec-
ondary specificity and recognize amino acid residues 
removed from the P1 residue. 
It is an object of this invention to discover new prote-
ase inhibitors, especially blood coagulation enzyme 
inhibitors, which can act as anticoagulants in vitro and 
in vivo. Such inhibitors could be used in prevention of 
thrombosis during periods of stasis and/or endothelial 
damage in segments of vasculature. They could also be 
used in an adjunct to fibrinolytic therapy to prevent 
acute coronary or peripheral artery reclosure. The in-
hibitors of this invention would be useful as the sole 
method of maintaining anticoagulation in extracorpo-
real blood circuits such as the kidney hemodialysis, and 
heart lung bypass. Such inhibitors could also be used as 
alternate anticoagulants when conventional anticoagu-
lation with heparin or coumarin fail or is contraindi-
cated. The inhibitors of this invention would also be 
useful in the therapy for disseminated intravascular 
coagulation syndromes (DIC). They could also be used 
in prophylaxis against thrombosis in high risk situations 
involving myocardium (e.g. unstable angina). 
It is another object of this invention to discover new 
protease inhibitors, especially elastase inhibitors, tryp-
3 
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tase inhibitors, chymase inhibitors and plasmin inhibi-
tors. These inhibitors are useful for controlling tissue 
damage and various inflammatory conditions mediated 
by proteases particularly elastases. The inhibitors of this 
invention would be useful for treating diseases related S 
to plasmin such as tumor invasiveness and blistering. 
The inhibitors of this invention would also be useful for 
controlling hormone processing by serine proteases and 
for treating diseases related to tryptases and chymases 10 
such as inflammation and skin blistering. The inhibitors 
of this invention are useful for treating diseases related 
to tryptases and caused by viral infection such as AIDS. 
It is a further object of this invention to find a novel 
group of specific inhibitors useful in vitro for inhibiting lS 
trypsin, elastase, chymotrypsin and other serine pro-
teases of similar specificity and for inhibiting serine 
proteases in general. Such inhibitors could be used to 
identify new proteolytic enzymes encountered in re-
search. They could also be used in research and indus- 20 
trially to prevent undesired proteolysis that occurs dur-
ing the production, isolation, purification, transport and 
storage of valuable peptides and proteins. Such proteo-
lysis often destroys or alters the activity and/or func-
tion of the peptides and proteins. Uses would include 2S 
the addition of the inhibitors to antibodies, enzymes, 
plasma proteins, tissue extracts or other proteins and 
peptides which are widely sold for use in clinical analy-
ses, biomedical research, and for many other reasons. 
For some uses a specific inhibitor would be desirable, 3o 
while in other cases, an inhibitor with general specific-
ity would be preferred. 
4 
0 
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or a pharmaceutically acceptable salt, wherein 
(I) 
R is selected from the group consisting of H, OH, 
NH1, N02, halogen, C1-6 alkoxy, Ct-6 fluorinated alk-
oxy, Ct-6 alkyl, O=C=N-, S==C=N-, AA-NH-, 
AA-AA-NH-, AA-0-, AA-AA-0-, 
M-NH-, M-AA-NH-, M-AA-AA-NH-, 
M-0-, M-AA-0-, M-AA-AA-0-, 
wherein AA represents alanine, valine, leucine, iso-
leucine, praline, methionine, phenylalanine, tryptophan, 
glycine, serine, threonine, cysteine, tyrosine, aspara-
gine, glutamine, aspartic acid, glutamic acid, lysine, 
arginine, histidine, beta-alanine, norleucine, norvaline, 
phenylglycine, alpha-aminobutyric acid, epsilon-
aminocaproic acid, citrulline, hydroxyproline, ornithine 
or sarcosine, 
wherein M represents NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X-NH-CS-, X-N-
H-S02-, X-CO-, X-CS-, X-S02-, 
X-0-CO-, or X-0-CS-, 
wherein X represents Ct-6 alkyl, Ct-6 fluoroalkyl, 
Ct-6 alkyl substituted with K, Ct-6 fluoroalkyl substi-
tuted with K, phenyl, phenyl substituted with J, phenyl 
disubstituted with J, phenyl trisubstituted with J, naph-
thyl, naphthyl substituted with J, naphthyl disubstituted 
with J, naphthyl trisubstituted with J, Ct-6alkyl with an DETAILED DESCRIPTION OF THE 
INVENTION 3S attached phenyl group, Ct-6 alkyl with two attached 
phenyl groups, Ct-6 alkyl with an attached phenyl 
group substituted with J, or C1-6 alkyl with two at-
tached phenyl groups substituted with J, 
Isocoumarins with cationic substituents have been 
found to be excellent inhibitors of several serine pro-
teases including bovine trypsin, bovine thrombin, 
human thrombin, bovine factor Xa, human factor Xa, 40 
human factor Xia, human factor Xlla, human factor 
VIia, porcine pancreatic kallikrein, human plasma kalli-
krein, human plasma plasmin, human tissue plasmino-
gen activator, Complement proteins Ctr, CtS, D, B, and 
Cl), sheep lymph tryptase, human lung tryptase, rat 4S 
skin tryptase, mouse cytotoxic lymphocyte granzyme 
A, human cytotoxic lymphocyte granzyme A, human 
cytotoxic lymphocyte Q3 l tryptase. Isocoumarins with 
hydrophobic substituents have been found to be excel-
lent inhibitors of several serine proteases including SO 
human leukocyte elastase, porcine pancreatic elastase, 
bovine chymotrypsin, human leukocyte cathepsin G, 
rat mast cell protease II, human skin chymase, and 
human lung chymase. These compounds inhibit the SS 
serine proteases by reaction with the active site serine to 
form an acyl enzyme, which in some cases may further 
react with another active site nucleophile to form an 
additional covalent bond. These structures may be used 
in vivo to treat diseases resulting from uncontrolled 60 
blood coagulation or diseases caused by uncontrolled 
proteolysis by elastase, chymotrypsin, trypsin and re-
lated serine proteases. These inhibitors may be used in 
vitro to prevent proteolysis which occurs in the process 
of production, isolation, purification, storage or trans- 6S 
port of peptides and proteins. The novel substituted 
isocoumarin and related heterocyclic compounds have 
the following structural formula: 
wherein J represents halogen, COOR, OH, CN, N02, 
NH2, C1-6alkyl, C1-6alkoxy, Ct-6alkylamine, C1-6dialk-
ylamine, C1-6 alkyl-0-CO-, or Ct-6 alkyl-
0-CO-NH-, 
wherein K represents halogen, COOR, OH, CN, 
N02, NH2, Ct-6 alkoxy, Ct-6 alkylamine, C1-6 dialkyla-
mine, or C1-6 alkyl-0-CO-, or Ct-6 alkyl-
0-CO-NH-, 
Z is selected from the group consisting of C1-6 alkoxy 
with an amino group attached to the alkoxy group, Ct-6 
alkoxy with an isothiureido group attached to the alk-
oxy group, C1-6alkoxy with a guanidino group attached 
to the alkoxy group, Ct-6alkoxy with an amidino group 
attached to the alkoxy group, Ct-6 alkyl with an amino 
group attached to the alkyl group, Ct-6 alkyl with an 
isothiureido group attached to the alkyl group, Ct-6 
alkyl with an guanidino group attached to the alkyl 
group, Ct-6alkyl with an amidino group attached to the 
alkyl group, and 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH and methoxy. 
Alternately the novel isocoumarin and related heter-
ocyclic compounds are represented by structure (I) 
where, 
wherein R is selected from the group consisting of 
O=C=N-, S==C=N-, M-NH-, 
M-AA-NH-, M-AA-AA-NH-, M-0-, 
M-AA-0, M-AA-AA-0-, 
wherein M represents NH2-CO-, NH1-CS-, 
NH2-S02-, X-NH-CO-, X-NH-CS-, X-N-
5 
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6 
group substituted with J, or C1-6 alkyl with two at-
tached phenyl groups substituted with J, 
wherein J represents halogen, COOH, OH, CN, N02, 
NH2, C1-6alkyl, C1-6alkoxy, C1-6alkylamine, C1-6dialk-
ylamine, Ct-6 alkyl-0-CO-, C1-6 alkyl-
0-CO-NH-, or Ct-6 alkyl-S-, 
H-S02-, X-CS-, X-0-CO-, X-0-CS-, 
benzoyl with J substituent attached to benzoyl group, 
phenylsulfonyl with J substituent attached to phenylsul-
fonyl group, C1-6 alkylsulfonyl with K substituent at-
tached to C1-6 alkylsulfonyl group, C2-6 alkanoyl with 5 
phenyl group attached to C2-6 alkanoyl group, or C2-6 
alkanoyl with phenyl group substituted with J attached wherein K represents halogen, COOH, OH, CN, 
N02, NH2, C1-6 alkoxy, C1-6 alkylamine, Ct-6 dialkyla-
mine, Ct-6 alkyl-0-CO-, or Ct-6 alkyl-0-CO-NH, 
10 C1-6 alkyl-S-, or tosylamino, 
to C2-6 alkanoyl group, 
wherein X represents C1-6 alkyl, C1-6 fluoroalkyl, 
C1-6 alkyl substituted with K, C1-6 fluoroalkyl substi-
tuted with K, 9-fluorenylmethyl, phenyl, phenyl substi-
tuted with J, phenyl disubstituted with J, phenyl trisub-
stituted with J, naphthyl, naphthyl substituted with J, 
naphthyl disubstituted with J, naphthyl trisubstituted 
with J, Ct-6 alkyl with an attached phenyl group, Ct-6 15 
alkyl with two attached phenyl groups, Ct-6 alkyl with 
an attached phenyl group substituted with J, or C1-6 
alkyl with two attached phenyl groups substituted with 
J, . 
wherein J represents halogen, COOH, OH, CN, N02, 20 
NH2, C1-6alkyl, C1-6alkoxy, C1-6alkylamine, Ct-6dialk-
ylamine, Ct-6 alkyl-0-CO-, Ct-6 alkyl-
0-CO-NH-, or C1-6 alkyl-S-, wherein K repre-
sents halogen, COOH, OH, CN, N02, NH2, C1-6alkyla- 25 
mine, Ct-6 dialkylamine, C1-6 alkyl-0-, C1-6 alkyl-
0-CO-NH, Ct-6 alkyl-S-, or tosylamino, 
wherein AA represents alanine, valine, leucine, iso-
leucine, proline, methionine, phenylalanine, tryptophan, 
glycine, serine, threonine, cysteine, tyrosine, aspara- 30 gine, glutamine, aspartic acid, glutamic acid, lysine, 
arginine, histidine, beta-alanine, norleucine, norvaline, 
phenylglycine, alpha-aminobutyric acid, epsilon-
aminocaproic acid, citrulline, hydroxyproline, ornithine 
or sarcosine, 35 
Z is Ct-6 alkyl, Ct-6 alkoxy, Ct-6 alkyl with a phenyl 
group attached to the Ct-6 alkoxy, C1-6 alkoxy with a 
phenyl group attached to the Ct-6 alkoxy, and 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH and methoxy. 40 
Alternately the novel isocoumarin and related heter-
ocyclic compounds are represented by structure (I) 
where, 
R is selected from the group consisting of OH, NH2, 
N02, O=C=N-, S=C=N-, AA-NH-, 45 
AA-AA-NH, AA-0-, AA-AA-0-, 
M-NH-, M-AA-NH-, M-AA-AA-NH-, 
M-0-, M-AA-0, M-AA-AA-0-, 
wherein AA represents alanine, valine, leucine, iso-
leucine, proline, methionine, phenylalanine, tryptophan, so 
glycine, serine, threonine, cysteine, tyrosine, aspara-
gine, glutamine, aspartic acid, glutamic acid, lysine, 
arginine, histidine, beta-alanine, norleucine, norvaline, 
phenylglycine, alpha-aminobutyric acid, epsilon-
aminocaproic acid, citrulline, hydroxyproline, ornithine SS 
or sarcosine, 
wherein M represents NH2-CO-, NH2-CS-, 
NH2S02-, X-NH-CO-, X-NH-CS-, X-N-
H-S02-, X-CO-, X-CS-, X-S02-, 
X-0-CO-, or X-0-CS-, 60 
wherein X represents Ct-6 alkyl, C1-6 fluoroalkyl, 
Ct-6 alkyl substituted with K, Ct-6 fluoroalkyl substi-
tuted with K, phenyl, phenyl substituted with J, phenyl 
disubstituted with J, phenyl trisubstituted with J, naph-
thyl, naphthyl substituted with J, naphthyl disubstituted 65 
with J, naphthyl trisubstituted with J, C1-6alkyl with an 
attached phenyl group, C1-6 alkyl with two attached 
phenyl groups, Ct-6 alkyl with an attached phenyl 
Z is selected from the group consisting of C1-6 alkoxy 
with a halogen attached to the alkoxy group, C1-6 alkyl 
with a halogen attached to the alkyl group, Ci-6 alkoxy 
with an attached Ct-6 alkoxy group substituted with Q, 
wherein Q represents H, or Ct-6 alkoxy, and 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH and methoxy. 
Alternately the novel isocoumarin and related heter-
ocyclic compounds are represented by structure (I) 
where, 
R is selected from the group consisting of -N-
H-C( NH)NH2, -C( NH)NH2, Ct-6 alkyl with an 
amino group attached to the Ct-6 alkyl, C1-6 alkyl with 
an isothiureido group of the formula 
-S-C( NH)NH2 attached to the alkyl group, 
Z is selected from the group consisting of H, halogen, 
C1-6 alkyl, C1-6 fluorinated alkyl, Ct-6 alkyl substituted 
with K, C1-6 fluorinated alkyl substituted with K, C1-6 
alkoxy, Ct-6 fluorinated alkoxy, Ct-6 alkoxy substituted 
with K, Ct-6 fluorinated alkoxy substituted with K, Ct-6 
alkyl with a phenyl group attached to the alkyl group, 
C1-6 alkoxy with a phenyl group attached to the alkoxy 
group, Ct-6 alkyl with an attached phenyl group substi-
tuted with J, Ct-6 alkyl with an attached phenyl group 
disubstituted with J, Ct-6 alkoxy with an attached 
phenyl group substituted with J, Ct-6 alkoxy with an 
attached phenyl group disubstituted with J, 
wherein J represents halogen, COOH, OH, CN, N02, 
NH2, C1-6alkyl, Ct-6alkoxy, C1-6alkylamine, C1-6dialk-
ylamine, Ct-6 alkyl-0-CO-, Ct-6 alkyl-
0-CO-NH-, or Ct-6 alkyl-S-, 
wherein K represents halogen, COOH, OH, CN, 
N02, NH2, Ct-6 alkoxy, Ct-6 alkylamine, C1-6 dialkyla-
mine, C1-6 alkyl-0-CO-, or Ct-6 alkyl-
0-CO-NH-, C1-6 alkyl-S-, or tosylamino, and 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH, and methoxy. 
Alternatively the novel isocoumarin and related het-
erocyclic compounds are represented by structure (I) 
where, 
R is selected from the group consisting of -N-
H-C( NH)NH2, -C( NH)NH2, C1-6 alkyl with an 
amino group attached to the C1-6 alkyl, C1-6 alkyl with 
an isothiureido group attached to the C1-6 alkyl, 
Z is selected from the group consisting of Ct-6 alkoxy 
with an amino group attached to the alkoxy group, C1-6 
alkoxy with an isothiureido group attached to the alk-
oxy group, C1-6alkoxy with a guanidino group attached 
to the alkoxy group, C1-6 alkoxy with an amidino group 
attached to the alkoxy group, C1-6 alkyl with an amino 
group attached to the alkyl group, C1-6 alkyl with an 
isothiureido group attached to the alkyl group, C1-6 
alkyl with a guanidino group attached to the alkyl 
group, C1-6alkyl with an amidino group attached to the 
alkyl group, and 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH and methoxy. 
7 
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Alternately the novel isocoumarin and related heter- (1969); 7-nitro and 7-aminoisocoumarin, Choksey and 
ocyclic compounds are represented by structure (I) Usgaonkar, Ind. J. Chem. 14B, pp 596-598 (1976), the 
where, preceding articles are incorporated herein by refer-
R is biotin-spacer-T, ence). 
wherein T represents -NH-, -0-, or -S-, 5 A number of other substituted isocoumarins have 
Spacer represents -[NH-(CH2)n-CO]n-, -[N- been prepared recently for inhibition of serine proteases 
H-(CH2)n-NH-CO]n-, -(NH-414-CO)n-, (3-chloroisocoumarin, Harper, Hemmi, and Powers, J. 
-(NH-C6l4-NH-CO)n-, -NH-(CH2-)n-CO-NH-(CH2)n-NH-CO-, -NH-(CH2_ Am. Chem. Soc. 105, pp 6518-6520 (1983); 3,4-
) CO NH (CH) NH (CH) N dichloroisocoumarin, Harper, Hemmi, and Powers, 
n- - -
2 3
- -
2 3
- -
10 Biochemistry 24, pp 1831-1841 (1985)·, 3-alkoxy-7-H-CO-CH2CH2-CO-, or -(AA)n-, 
where n= 1-6, amino-4-chloroisocoumarin, Harper and Powers, J. 
wherein AA represents alanine, valine, leucine, iso- Am. Chem. Soc. 106, pp 7618-7619 (1984), Harper and 
leucine, proline, methionine, phenylalanine, tryptophan, Powers, Biochemistry 24, 7200-7213 (1983); substituted 
glycine, serine, threonine, cysteine, tyrosine, aspara- 15 isocoumarins with basic groups such as aminoalkoxy, gine, glutamine, aspartic acid, glutamic acid, lysine, guanidino or isothiureidoalkoxy, Kam, Fujikawa and 
arginine, histidine, beta-alanine, norleucine, norvaline, Powers, Biochemistry 27, pp 2547-2557 (1988); 7-sub-
phenylglycine, alpha-aminobutyric acid, epsilon- stituted 3-alkoxy-4-chloroisocoumarins, Powers, Kam, 
aminocaproic acid, citrulline, hydroxyproline, ornithine Narasimhan, Oleksyszyn, Hernandez and Ueda, J. Cell 
or ~rcosine, . . 20 Biochem. 39, pp 33-46 (1989), Powers, Oleksyszyn, 
Z is selected from ~he group cons1stmg ofH, hal.ogen, Narasimhan, Kam, Radhakrishnan and Meyer, Jr. Bio-
C!-6 alkyl, Ct-6 flu?nnated alkyl, C!-6 alkyl ~ubst1tuted chemistry 29, 3108-3118 (1990), the preceding articles 
with K, C1-6 fluo~nated alkyl substituted with K? Ct-6 are incorporated herein by reference; Powers and Har-
al~oxy, C1-6 fluo~nated alkoxy, Ct-6.alkoxy ~ubst1tuted per, U.S. Pat. No. 4,596,822; Powers and Kam, U.S. Pat. 
with K,_ C1-6 fluonnated alkoxy substituted with K, C1.6 25 No. 4,845,242 which are also inco orated b refer-
alkyl with a phenyl group attached to the alkyl group, ) rp y 
Ct-6 alkoxy with a phenyl group attached to the alkoxy ence · . . 
group, c1.6 alkyl with an attached phenyl group substi- . The_ following compounds are representative of the 
tuted with J, Ct-6 alkyl with an attached phenyl group invention: 
disu]:>stituted with J, C1-6 alkoxy with an attached 30 phenyl group substituted with J, Ct-6 alkoxy with an 
attached phenyl group disubstituted with J, 
wherein J represents halogen, COOH, OH, CN, N02, 
NH2, C1-6alkyl, C1-6alkoxy, C1.6alkylamine, C1.6dialk-
ylamine, C1.6 alkyl-0-CO-, Ct-6 al- 35 kyl-0-CO-NH-, or C1-6 alkyl-S-, 
wherein K represents halogen, COOH, OH, CN, 
N02, NH2, Ct-6 alkoxy, C1-6 alkylamine, C1.6 dialkyla-
mine, Ct-6 alkyl-0-CO-, or Ct-6 alkyl-
0-CO-NH-, C1.6 alkyl-S-, or tosylamino, and 
Y is selected from the group consisting of H, halogen, 40 
trifluoromethyl, methyl, OH, and methoxy. 
The compounds of Formula (I) can also contain one 
or more substituents at position B as shown in the fol-
0 
RW~'o I N~+ 
II # # O-(CH2)n-S-C-NH2 
Cl 
CiTEtO IC (n = 2); CiTPrO IC (n = 3) 
7-(benzylcarbamoylamino )-4-chloro-3-(3-isothiureido-
propoxy )isocoumarin (PhCH2NHCONH-CiT-
PrOIC) 
lowing structure: 
7-(phenylcarbamoylamino )-4-chloro-3-(3-isothiureido-
propoxy )isocoumarin (PhNHCONH-CiTPrOIC) 
7-(acetylamino )-4-chloro-3-(3-isothiureidopropox-
45 y)isocoumarin (CH3CONH-CiTPrOIC) 
B 0 7-(3-phenylpropionylamino )-4-chloro-3-(3-isothiureido-
propoxy )isocoumarin (PhCH2CH2CONH-CiT-
PrOIC) RW' I ~ o 
B # # Z 
B y 
50 7-(phenylacetylamino )-4-chloro-3-(3-isothiureido-propoxy )isocoumarin (PhCH2CONH-CiTPrOIC) 
7-(L-phenylalanylamino )-4-chloro-3-(3-isothiureido-
propoxy )isocoumarin (L-Phe-NH-CiTPrOIC) 
7-(N-t-butyloxycarbonyl-L-phenylalanylamino )-4-
chloro-3-(3-isothiureidopropoxy )isocoumarin (Boc-
L-Phe-NH-CiTPrOIC) 
wherein electronegative substituents such as N02, CN, 
Cl, COOR, and COOH will increase the reactivity of 55 
the isocoumarin, and electropositive substituents such 
as NH2, OH, alkoxy, thioalkyl, alkyl, alkylamino, and 
dialkylamino will increase its stability. Neutral substitu-
ents could also increase the stability of acyl enzyme and 
improve the effectiveness of the inhibitors. 60 
Other substituted isocoumarins have been prepared 
earlier for other purposes (illustrative examples: 3-
chloroisocoumarin, Davies and Poole, J. Chem. Soc., 
pp 1616-1629 (1928); 3-chloro and 3,4-
dichloroisocoumarin, Milevskaya, Belinskaya, and 65 
Yagupol'skii, Zhur. Org. Khim. 9, pp 2145-2149 (1973); 
3-methyl and 4-carboxy-3-methylisocoumarin, Tirod-
kar and Usgaonkar, Ind. J. Chem. 7, pp 1114-1116 
7-(D-phenylalanylamino )-4-chloro-3-(3-isothiureido-
propoxy)isocoumarin (D-Phe-NH-CiTPrOIC) 
7-(N-t-butyloxycarbonyl-D-phenylalanylamino )-4-
chloro-3-(3-isothiureidopropoxy)isocoumarin (Boc-
D-Phe-NH-CiTPrOIC) 
7-(benzylcarbamoylamino)-4-chloro-3-(2 -isothiureido-
ethoxy)isocoumarin (PhCH2NHCONH-CiTEtOIC) 
7-(phenylcarbamoylamino )-4-chloro-3-(2-isothiureidoe-
thoxy )isocoumarin (PhNHCONH-CiTEtOIC) 
7-(isopropylcarbamoylamino )-4-chloro-3-(2-isothi-
ureidoethoxy)isocoumarin ((CH3)2CHNHCONH-
CiTEtOIC) 
9 
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7-(phenylacetylamino)-4-chloro-3-(2-isothiureidoethox- 7-methoxysuccinylamino-4-chloro-3-methox-
y)isocoumarin (PhCH2CONH-CiTEtOIC) yisocoumarin 
7-(L-phenylalanylamino )-4-chloro-3-(2-isothiureidoe- 7-methoxyglutary lamino-4-chloro-3-methoxyisocouma-
thoxy )isocoumarin (L-Phe-NH-CiTEtOIC) rin 
7-(N-t-butyloxycarbonyl-L-phenylalanylamino)-4- 5 7-(3-phenylglutaryl)amino-4-chloro-3-methox-
chloro-3-(2-isothiureidoethoxy )isocoumarin (Boc-L- yisocoumarin 
Phe-NH-CiTEtOI C) 7-(m-methoxycarbonylaminobenzoy l)amino-4-chloro-
7-(D-phenylalanylamino )-4-chloro-3-(2-isothiureidoe- 3-methoxyisocoumarin 
thoxy)isocoumarin (D-Phe-NH-CiTEtOIC) 7-ethoxycarbonylamino-4-chloro-3-ethoxyisocoumarin 
7-(N-t-butyloxycarbonyl-D-phenylalanylamino)-4- 10 7-ethylthiocarbamoylamino-4-chloro-3-ethox-
chloro-3-(2-isothiureidoethoxy )isocoumarin (Boc-D- yisocoumarin 
Phe-NH-CiTEtOIC) 7-phenylthiocarbamoylamino-4-chloro-3-ethox-
7-(N-t-buty loxycarbony 1-L-alanyl-L-alany !amino )-4- yisocoumarin 
chloro-3-(2-isothiureidoethoxy)isocoumarin (Boe- 7-dihydrocinnamoylamino-4-chloro-3-propylox-
Ala-Ala-NH-CiTEtOIC) 15 yisocoumarin 
7-(L-alanyl-L-alanylamino )-4-chloro-3-(2-isothiureido- 7-ethoxycarbonylamino-4-chloro-3-propylox-
ethoxy)isocoumarin (Ala-Ala-NH-CiTEtOIC) yisocoumarin 
7-(l-naphthylcarbamoylamino )-4-chloro-3-(2-isothi- 7-ethylcarbamoylamino-4-chloro-3-propylox-
ureidoethoxy )isocoumarin (NaphthylNH- yisocoumann 
CiTEtOIC) 20 7-phenylcarbamoylamino-4-chloro-3-propylox-
7-((S)-a-methylbenzylcarbamoylamino )-4-chloro-3-(2- yisocoumarin 
isothiureidoethoxy)isocoumarin · (S- 7-phenylthiocarbamoylamino-4-chloro-3-propylox-
C6Hs(CH3)CHNHCONH-CiTEtOIC) yisocoumarin 
7-((R)-a-methylbenzylcarbamoylamino)-4-chloro-3-(2- 7-benzylthiocarbamoylamino-4-chloro-3-propylox-
isothiureidoethoxy)isocoumarin (R- 25 yisocoumarin 
4Hs(CH3)CHNHCONH-CiTEtOIC) 7-(m-nitrobenzoyl)amino-4-chloro-3-propylox-
7-dansylamino-4-chloro-3-(2-isothiureidoethox- yisocoumarin 
y)isocoumarin (DansylNH-CiTEtOIC) 7-[(2-thiomethyl)acetyl]amino-4-chloro-3-propylox-
7-phenylthiocarbamoylamino-4-chloro-3-(2-isothi- yisocoumarin 
ureidoethoxy)isocoumarin (PhNHCSNH- 30 7-(N-t-butyloxycarbonyl-valyl)amino-4-chloro-3-
CiTEtOIC) propyloxyisocoumarin 
7-(m-carboxyphenylthiocarbamoyl)amino-4-chloro-3- 7-nitro-4-chloro-3-(2-bromoethoxy)isocoumarin 
(2-isothiureidoethoxy)isocoumarin (m-COOH- 7-amino-4-chloro-3-(2-bromoethoxy)isocoumarin 
PhNHCSNH-CiTEtOIC) 7-t-butylcarbamoylamino-4-chloro-3-(2-bromoethox-
7-(p-carboxyphenylthiocarbamoyl)amino-4-chloro-3- 35 y)isocoumarin 
(2-isothiureidoethoxy )isocoumarin (p-COO H- 7-isopropylcarbamoylamino-4-chloro-3-(2-bromoe-
PhNHCSNH-CiTEtOI C) thoxy)isocoumarin 
7-(L-alanylamino)-4-chloro-3-methoxyisocoumarin 7-phenylcarbamoylamino-4-chloro-3-(2-bromoethox-
7-(glycylamino)-4-chloro-3-methoxyisocoumarin y)isocoumarin 
7-isocyanato-4-chloro-3-methoxyisocoumarin 40 7-benzylcarbamoylamino-4-chloro-3-(2-bromoethox-
7-ethoxycarbonylamino-4-chloro-3-methoxyisocouma- y )isocoumarin 
rin 7-(R-a-methylbenzyl)carbamoylamino-4-chloro-3-(2-
7-phenoxycarbonylamino-4-chloro-3-methox- bromoethoxy )isocoumarin 
yisocoumarin 7-(S-a-methylbenzyl)carbamoylamino-4-chloro-3-(2-
7-bc;nzyloxycarbonylamino-4-chloro-3-methox- 45 bromoethoxy)isocoumarin 
yisocoumarin 7-naphthylcarbamoylamino-4-chloro-3-(2-bromoethox-
7-carbamoylamino-4-chloro-3-methoxyisocoumarin y )isocoumarin 
7-methylcarbamoylamino-4-chloro-3-methox- 7-t-butylacetylamino-4-chloro-3-(2-bromoethox-
yisocoumarin y )isocoumarin 
7-ethylcarbamoylamino-4-chloro-3-methoxyisocouma- 50 7-phenylacetylamino-4-chloro-3-(2-bromoethox-
rin y)isocoumarin 
7-isopropylcarbamoylamino-4-chloro-3-methox- 7-(N-t-butyloxycarbonyl-D-phenylalanyl)amino-4-
yisocoumarin chloro-3-(2-bromoethoxy )isocoumarin 
7-t-butylcarbamoylamino-4-chloro-3-methox- 7-(N-t-butyloxycarbonyl-L-phenylalanyl)amino-4-
yisocoumarin 55 chloro-3-(2-bromoethoxy)isocoumarin 
7-phenylcarbamoylamino-4-chloro-3-methox- 7-(N-t-butyloxycarbonyl-L-alanylalanyl)amino-4-
yisocoumarin chloro-3-(2-bromoethoxy )isocoumarin 
7-(N-benzyl-N-phenylethylcarbamoyl)amino-4-chloro- 7-dansylamino-4-chloro-3-(2-bromoethoxy)isocoumarin 
3-methoxyisocoumarin 7-phenylthiocarbamoylamino-4-chloro-3-(2-bromoe-
7-heptafluorobutyroylamino-4-chloro-3-methox- 60 thoxy)isocoumarin 
yisocoumarin 7-(m-carboxyphenyl)thiocarbamoylamino-4-chloro-3-
7-(9-fluorenylmethoxycarbonyl)amino-4-chloro-3- (2-bromoethoxy)isocoumarin 
methoxyisocoumarin 7-(p-carboxyphenyl)thiocarbamoylamino-4-chloro-3-
7-(N-tosyl-a-phenylglycyl)amino-4-chloro-3-methox- (2-bromoethoxy)isocoumarin 
yisocoumarin 65 7-nitro-4-chloro-3-(3-bromopropoxy )isocoumarin 
7-( o-phthalyl)amino-4-chloro-3-methoxyisocoumarin 7-amino-4-chloro-3-(3-bromopropoxy )isocoumarin 
7-(o-methoxyphthalyl)amino-4-chloro-3-methox- 7-phenylcarbamoylamino-4-chloro-3-(3-bromopropox-
yisocoumarin y )isocoumarin 
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7-benzylcarbamoylamino-4-chloro-3-(3-bromopropox- the effective inhibition of the proteolytic function of 
y)isocoumarin human plasma plasmin and human tissue plasminogen 
7-acetylamino-4-chloro-3-(3-bromopropoxy)isocouma- activator. Compounds of Formula (I) have anti-viral 
rin and anti-tumor activity as shown in Table VII by effec-
7-phenylacetylamino-4-chloro-3-(3-bromopropox- 5 tive inhibition of proteolytic function of mouse gran-
y)isocoumarin zyme A, human granzyme A and human Q31 tryptase, 
7-dihydrocinnamoylamino-4-chloro-3-(3-bromo- which are involved in cell-mediated killing. 
propoxy)isocoumarin It has been found that compounds of Formula (I) 
7-(N-t-butyloxycarbonyl-D-phenylalanyl)amino-4- have anti-inflammatory activity and can be used to treat 
chloro-3-(3-bromopropoxy)isocoumarin 10 and control emphysema, adult respiratory distress syn-
7-(N-t-butyloxycarbonyl-L-phenylalanyl)amino-4- drome and rheumatoid arthritis as shown in Table IV, 
chloro-3-(3-bromopropoxy)isocoumarin X, XI, XII, XIII and XVI by effective inhibition of the 
7-nitro-4-chloro-3-(2-bromoisopropoxy)isocoumarin proteolytic function of human leukocyte elastase and 
7-amino-4-chloro-3-(2-bromoisopropoxy)isocoumarin human cathepsin G. Compounds of Formula (I) are 
7-amino-4-chloro-3-(2-methoxy)ethoxyisocoumarin 15 effective in the theraputic use for pancreatitis by inhibit-
7-amino-4-chloro-3-[2-(2-methoxyethoxy)etox- ing the proteolytic function of chymotrypsin and pan-
y]isocoumarin creatic elastase as shown in Table IV, X, XI, XII, XIII, 
3-(3-aminopropoxy)isocoumarin and XVI. Compounds of Formula (I) are also effective 
3-(3-aminopropoxy)-4-chloroisocoumarin in the prevention of unnecessary proteolysis caused by 
3-(2-isothiureidoethoxy)-4-chloroisocoumarin 20 chymotrypsin and elastase in the process of purification, 
3-(3-isothiureidopropoxy)-4-chloroisocoumarin transport and storage of peptides and proteins as shown 
7-amino-4-chloro-3-(2-isothiureidoethoxy)isocoumarin in Table IV, X, XI, XII, XIII, and XVI by effective 
7-amino-4-chloro-3-(3-isothiureidopropoxy)isocouma- inhibition of chymotrypsin and elastase. 
rin Compounds of Formula (I) with R group consisting 
7-guanidino-3-methoxyisocoumarin 25 of biotinylamino or alkanoylamino with biotinylamino 
7-guanidino-4-chloro-3-methoxyisocoumarin group attached to alkanoylamino, Y group of Cl, and Z 
7-guanidino-3-ethoxyisocoumarin group of phenylethoxy group are effective in the inhibi-
7-guanidino-4-chloro-3-ethoxyisocoumarin tion ofrat granule chymase as shown in Table XIV. The 
7-guanidino-3-(2-phenylethoxy)isocoumarin reactivation of inhibited rat granule chymase by these 
7-guanidino-4-chloro-3-(2-phenylethoxy)isocoumarin 30 biotin isocoumarins in the presence ofhydroxylamine as 
7-biotinylamino-4-chloro-3-propyloxyisocoumarin shown in Table XV is useful in the purification of these 
7-biotinylamino-4-chloro-3-(2-phenylethoxy)isocouma- enzymes from rat granules by applying the inhibited 
rin granules to the avidin beads, where the biotinylated 
7-(6-biotinylaminocaproyl)amino-4-chloro-3-ethox- enzymes form tight complex with avidin and retain on 
yisocoumarin 35 the column. Finally the enzyme can be reactivated and 
7-(6-biotinylaminocaproyl)amino-4-chloro-3-propylox- eluted out with hydroxylamine solution. 
yisocoumarin Inactivation rates of serine proteases by substituted 
7-(6-biotinylaminocaproyl)amino-4-chloro-3-(2- isocoumarins were measured by the incubation method. 
phenylethoxy)isocoumarin An aliquot of inhibitor (25 or 50 µI) in Me2SO was 
It has been found that compounds of Formula (I) 40 added to a buffered enzyme solution (0.01-2.3 µ.M) to 
have anticoagulant activity as shown in Table I, VIII by initiate the inactivation. Aliquots (50 µ.l) were with-
effective inhibition of the proteolytic function of blood drawn at various intervals and the residual enzymatic 
coagulation enzymes in Hepes buffer. Compounds of activity was measured. Me2SO concentration in the 
Formula (I) also have anticoagulant effect in vitro as reaction mixture was 8-12% (v/v). 0.1 Hepes, 0.0lM 
shown in Table XIX by prolongation of the prothrom- 45 CaCJi, pH 7.5 buffer was utilized for trypsin and coagu-
bin time (PT) and activated partial thromboplastin time lation enzymes. O.lM Hepes, 0.5M NaCl, pH 7.5 was 
(APTT) in human, rabbit and pig plasma. Compounds utilized for other serine proteases. The inhibitor con-
of Formula (I) are effective in the treatment of organ centrations are shown in all the tables. Peptide thioes-
rejection and autoimmune diseases as shown in Table II ters or peptide nitroanilides with appropriate sequence 
by the effective inhibition of the proteolytic function of 50 were used as substrates for various serine proteases. All 
complement proteins. Compounds of Formula {I) are peptide thioester hydrolysis rates were measured with 
effective in the detection, prevention and inhibition of assay mixtures containing 4,4' -dithiodipyridine 
adult and infantile respiratory distress syndrome (a con- (E324= 19800M-lcm-1; Grasetti & Murray, Arch. Bio-
sequence of acute lung injuries) as shown in Table III, chem. Biophys. 119, pp 41-49 (1967)). Peptide 4-
and IX by the effective inhibition of the proteolytic 55 nitroanilide nitroanilide hydrolysis was measured at 410 
function of sheep lung lymph tryptase and human lung nm (E410=8800M-lcm-l; Erlanger et al., Arch. Bio-
tryptase. Sheep lung lymph tryptase is utilized as a chem. Biophys. 95, pp 271-278 (1961)). First order inac-
marker of lung capillary injury, and this is shown in the tivation rate constant Ckcbs) were obtained from plots of 
articles by Lesser et al., Am. Rev. Respir. Dis. 135, pp In (vtlv0) vs time, and the correlation coefficients were 
643-650 (1987) and by Orlowski et al., Arch. Biochem. 60 greater than 0.98. 
Biophys. 269, pp 125-136 (1989), which are incorpo- Table I and VIII shows the inactivation rate con-
rated herein by reference. Compounds of Formula {I) stants for several trypsin-like serine proteases inhibited 
are effective in treating a variety of blistering diseases as by isocoumarins substituted with basic groups. When 
shown in Table III, V, and IX by the effective inhibition the isocoumarin structure contains guanidino as R, or 
of proteolytic function of rat skin tryptase, human skin 65 amino-alkoxy, isothiureidoalkoxy as Z, and Cl as Y, the 
tryptase, rat mast cell protease II and human skin chy- compound is generally a good inhibitor for trypsin and 
mase. It has been found that compounds of Formula (I) blood coagulation enzymes and tryptases. The inactiva-
have anti-tumor activity as shown in Table VI, IX by tion of the enzyme is time dependent, and the kobsl[IJ 
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values are second order rate constants. In most cases, by substituted isocoumains. The structure with R group 
inactivation of the enzyme occurs at the inhibitor con- of guanidino, Z group of alkoxy, and Y group of chloro 
centration of 5-400 times the enzyme concentration and were potent inhibitors for rat mast cell protease II and 
the first order rate constant kobs is obtained. However, were moderate inhibitors for human skin chymase and 
in some cases, the inactivation was too fast to be mea- 5 human lung chymase. Table VI and IX show the inacti-
sured under first order rate condition ([I]> [E], the vation rate constants for human plasmin and human 
inactivation rate was measured either in the presence of tissue plasminogen activator by substituted isocouma-
substrate using the progress curve method as described rins. The structure with R groups of amino or substi-
by Tian and Tsou, Biochemistry 21, pp 1028-1032 tuted amino, hydrogen or guanidino, Z groups ofisothi-
(1982) or using the same concentration of enzyme and 10 ureidoalkoxy or alkoxy, and Y groups of chloro inhib-
inhibitor. 7-guanidino-4-chloro-3alkoxyisocoumarins ited both enzymes potently. Table VII shows the inacti-
are essentially stoichiometric inactivators of trypsin, vation of mouse granzyme A, human granzyme A and 
thrombin and kallikrein. The inactivation rate of the human Q31 tryptase by substituted isocoumarins. The 
enzyme depends on the substituents R, Zand Y. The isocoumarins with R groups of hydrogen, amino or 
structures with R groups of guanidino, and Y groups of 15 guanidino, Z groups of isothiureidoalkoxy or alkoxy, 
Cl are the best inhibitors for trypsin and all the coagula- and Y groups of chloro were potent inhibitors for all 
tion enzymes tested. The isocoumarins with R groups of three tryptases. 
phenylcarbamoylamino or S-methylbenzylcar- Table XI also shows the inactivation rate constants of 
bamoylamino, Y group of Cl and Z group of isothi- porcine pancreatic elastase (PPE), human leukocyte 
ureidoethoxy are the best inhibitors toward bovine and 20 elastase (HLE) inhibited by substituted isocoumarins. 
human thrombin. The isocoumarin with R group of The inactivation by these inhibitors was less efficient 
phenylcarbamoylamino, Y group of Cl and Z group of toward PPE than HLE. The structures with R group of 
isothiureidoethoxy is the potent inhibitor for human o-methoxyphthalylamino or phenylcarbamoylamino, Y 
factor Xa and human factor Xia. The isocoumarin with group of Cl, and Z group of methoxy are best inhibitors 
R group of L-Phe, Y group of Cl and Z group of isothi- 25 for PPE. The structures with R group of Tos-phenyl-
ureidoethoxy is the best inhibitor for human factor glycylamino or m-methoxycarbonylaminoben-
Xlla. zoylamino, Y group of Ci, and Z-group of methoxy are 
Table II shows the inactivation of complement prote- best at inhibiting HLE. The structure with R group of 
ins D, B, Cl, Cir, Cls, and their active fragments C2a, phenylthiocarbamylamino, Y group of Cl, and Z-group. 
Bb by substituted isocoumarins. The isocouimarin with 30 of ethoxy is the best inhibitor of PPE. Table XII shows 
R groups of amino or hydrogen, Z groups of isothi- the inhibition of PPE, HLE, chymotrypsin and cathep-
ureidopropoxy, and Y groups of chloro inhibit Ctr and sin G by substituted isocoumarins. It is unexpected that 
Cls quite potently. 7Guanidino-3-alkoxy-4- all the compounds with Y group of Cl and Z group of 
chloroisocoumarin inhibit Clf, Cls, B and Bb moder- propoxy are very potent inhibitors of HLE. The struc-
ately. Although 3-isothiureidoalkoxy-4- 35 ture with R group of phenylcarbamoylamino, or dihy-
chloroisocoumarins inhibit protein B and C2 poorly, drocinnamoylamino, Y group of Cl, and Z group of 
while other serine protease inhibitors such as 4-amidino- propoxy are the best inhibitors of HLE. However they 
phenylmethane sulfonyl fluoride (APMSF) and 3,4- are poor inhibitors of cathepsin G. The structure with R 
dichloroisocoumarin do not show any inhibition toward group of ethoxycarbonylamino, Y group of Cl and Z 
these two enzymes. Table III and IX show the inactiva- 40 group of propoxy is a good inhibitor for chymotrypsin. 
tion of sheep lung lymph tryptase, human lung tryptase Table XIII shows the inhibition of PPE, HLE, chy-
and rat skin tryptase by substituted isocoumarins. The motrypsin and cathepsin G by biotin isocoumarin deriv-
structure with a R group of guanidino, Z group of alk- atives. The compound with R group of o-
oxy, and Y group of chloro are good inhibitors for biotinylaminocaproylamino, Y group of Cl and Z group 
sheep lung lymph tryptase. The isocoumarins with R 45 of phenylethoxy is a good inhibitor for chymotrysin. 
groups of guanidino or amino, Z groups of alkoxy or The structure with R group of 6-biotinylaminoca-
isothiureidopropoxy, and Y groups of chloro are potent proylamino, Y group of Cl and Z group of propoxy or 
inhibitors for human lung tryptase and rat skin tryptase. ethoxy are best inhibitors for HLE. 
The structures with R groups of substituted amino, Y Table XIV shows the inhibition of rat granule chy-
group of Cl, and Z group of isothiureidoalkoxy are 50 mase and tryptase by biotin isocoumarin derivatives. 
good inhibitors for all three tryptases. Table IV an X The structure with R group of 6-biotinylaminoca-
show the inactivation rate constants for porcine pancre- proylamino, Y group of Cl and Z group of phenyle-
atic elastase (PPE), human leukocyte elastase (HLE), thoxy inactivated chymase instantly with 50% inhibi-
chymotrypsin and cathepsin G inhibited by substituted tion, and also inhibited tryptase very slowly. Table XV 
isocoumarins. Although the inactivation by the inhibi- 55 shows the reactivation of inhibited chymotrypsin and 
tors was less efficient toward these four enzymes than rat granule chymase by biotin isocoumarins in buffer 
trypsin-like enzymes, the isocoumarin with R group of and in the presence ofhydroxylamine. Inhibited chymo-
guanidino, Y group of Cl, and Z-group of ethoxy is a trypsin regained 40-85% of activity and inhibited rat 
good inhibitor for PPE, HLE and cathepsin G. The granule chymase regained 30-100% of activity in the 
structure with Z-group of 2-phenylethoxy is best at 60 presence of hydroxylamine. 
inhibiting chymotrypsin. The structure with R group of Table XVI shows the inhibition of PPE, HLE, chy-
phenylcarbamoylamino, Y group of Cl, and Z group of motrypsin and cathepsin G by isocoumarins substituted 
isothiureidoethoxy is a potent inhibitor for HLE. The with bromoalkoxy group. The structure with R group 
structure with R group of phenylacetylamino, Y group of R-methylbenzylcarbamylamino, Y group of Cl and Z 
of Cl, and Z-group of isothiureidopropoxy is best at 65 group ofbromoethoxy is the best inhibitor for PPE. It is 
inhibiting chymotrypsin. unexpected that all the compounds with Y group of Cl, 
Table V shows the inactivation of rat mast cell prote- Z-group of bromoethoxy are potent inhibitors of HLE, 
ase II, human skin chymase and human lung chymase especially the structure with R group of phenylcar-
15 
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bamoylamino is the most potent inhibitor ofHLE. The et al., N. Eng. J. Med. 304, pp 192-196 (1981); Rinaldo, 
structures with R group ofN02, Y group of Cl, Z group ibid 301, 900-909 (1982)). 
of 2-bromoisopropoxy and R group of phenylacetyl, Y It is known that in vitro activity of elastase inhibitors 
group of Cl, Z-group of bromopropoxy are the best at correlates with in vivo activity in animal models of 
inhibiting chymotrypsin. 5 emphysema and inflammation (Otterness et al., editors, 
Table XVII shows the half-life for the deacylation of Advances in Inflammation Research, Vol. 11, Raven 
inactivated elastase by 7-substituted isocoumarins. Only Press 1986, and this article is incorporated herein by 
the enzyme inactivated by compound with R group of reference). Prophylactic administration of an inhibitor 
phenylcarbamyl, Y group of Cl, and Z group of me- of elastase significantly diminishes the extent of elastase-
thoxy is stable with the half-life more than 48 hrs. 10 induced emphysema (Kleinerman et al., Am. Rev. 
The spontaneous hydrolysis rates of these substituted Resir. Dis. 121, pp 381-387 (1980); Lucey et al., Eur. 
isocoumarins in Hepes buffer, human and rabbit plasma Respir. J. 2, pp 421-427 (1989)). Thus the novel inhibi-
have been measured and summarized in Table XVIII. tors described here should be useful for the treatment of 
The isocoumarins with hydrogen at position 4 are 3-6 emphysema and inflammation. Elastase inhibitors have 
times more stable than the compounds with Cl at the 15 been used orally, by injection or by instillation in the 
same position. 7-Amino-4-chloro-3-(3-isothiureido- lungs in animal studies (Powers, Am. Rev. Respir. Dis., 
propoxy)isocoumarin is fairly stable in both human and 127, s54-s58 (1983); Powers and Bengali, Am. Rev. 
rabbit plasma. 7-Guanidino-4-chloro-3-alkox- Respir. Dis. 134, pp 1097-1100 (1986) and these two 
yisocoumarins are hydrolyzed in human and rabbit articles are incorporated herein by reference). The in-
plasma with half-lives of 5-8 min. The isocoumarins 20 hibitors described above can be used by any of these 
substituted with phenylcarbamoylamino or benzylcar- routes. 
bamoylamino at the 7-position are more stable than For treatment of blood coagulation-related diseases, 
7-amino-4-chloro-3-(3-isothiureidopropoxy)isocouma- tumor invasiveness, viral infection or inflammation, the 
rin. The isocoumarins substituted with 7-alkanoylamino compounds of Formula (I) or pharmaceutically accept-
group are less stable than the parent 7-amino com- 25 pound. able salts may be administered orally, topically or par-
Anticoagulants can prolong the clotting time of enterally. The term parenteral as used includes subcuta-
human plasma and play important roles in the treatment neous injection, intravenous, intramuscular, intrasternal 
of blood coagulation related diseases such as vascular injection or infusion techniques. The dosage depends 
clotting, cerebral infarction and coronary infarction 30 primarily on the specific formulation and on the object (Williams et al., Hemotalogy, 3rd ed. McGraw Hill, of the therapy or prophylaxis. The amount of the indi-
1983 and Ingram et al., Bleeding Disorders, 2nd ed. vidual doses as well as the administration is best deter-
Blackwell Scientific Publications, 1985. These two mined by individually assessing the particular case. 
books are incorporated herein by reference). The pres- The pharmaceutical compositions containing the ac-
ence of certain inhibitors of this invention in pig plasma 35 tive ingredient may be in a form suitable for oral use, for 
prolong the prothrombin time and activated partial example as tablets, troches, lozenges, aqueous or oily 
thromboplastin time quite effectively, therefore these suspensions, dispersible powders or granules, emulsions, 
compounds act as anticoagulants in vitro. Currently, hard or soft capsules or syrups or elixirs. Dosage levels 
there are few anticoagulant and antithrombotic drugs in of the order to 0.2 mg to 140 mg per kilogram of body 
use clinically, and the inhibitors described in this inven- 40 weight per day are useful in the treatment of above-
tion can be used as anticoagulants or antithrombotics in indicated conditions (10 mg to 7 gms per patient per 
mammals (including man). day). The amount of active ingredient that may be com-
Considerable evidence has shown that plasminogen bined with carrier materials to produce a single dosage 
activator, leukocyte elastase and/or related enzymes form will vary depending upon the host treated and the 
play a role in tumor cell metastasis (Salo, et al., Int. J. 45 particular mode of administration. 
Cancer 30, pp 669-673 (1973); Kao et al., Biochem. For injection, the therapeutic amount of the com-
Biophys. Res. Comm. 105, pp 383-389 (1982); Powers, pounds of Formula (I) or their pharmaceutically accept-
J. C. in Modification of Proteins, R. E. Feeney and J. R. able salts will normally be in the dosage range from 0.2 
Whitaker, eds., Adv. Chem. Ser 198, Amer. Chem. to 140 mg/kg of body weight. Administration is made 
Soc., Wash., D.C. pp 347-367 (1982)), therefore it is 50 by intravenous, intramuscular or subcutaneous injec-
suggested that compounds of this invention may have tion. Accordingly, pharmaceutical compositions for 
anti-tumor activity. parenteral administration will contain in a single dosage 
Pulmonary emphysema is a disease characterized by form about 10 mg to 7 gms of compounds of Formula 
progressive loss oflung elasticity due to the destruction (I) per dose. In addition to the active ingredient, these 
of lung elastin and alveoli. The destructive changes of 55 pharmaceutical compositions will usually contain a 
lung parentchyma associated with pulmonary emphy- buffer, e.g. a phosphate buffer which keeps the pH in 
sema are caused by uncontrolled proteolysis in lung the range from 3.5 to 7 and also sodium chloride, manni-
tissues (Janoff, Chest 83 pp 54-58 (1983)). A number of tol or sorbitol for adjusting the isotonic pressure. 
proteases has been shown to induce emphysema in ani- A composition for topical application can be formu-
mals (Marco et al., Am. Rev. Respir.Dis. 104, pp 60 lated as an aqueous solution, lotion, jelly or an oily 
595-598 (1971); Kaplan, J. Lab. Clin. Med. 82, pp solution or suspention. A composition in the form of an 
349-356 (1973)), particularly human leukocyte elastase aqueous solution is obtained by dissolving the com-
(Janoff, ibid 115, pp 461-478 (1977)). Leukocyte elas- pounds of Formula (I) or their pharmaceutically accept-
tase and other mediators of inflammation also appear to able salts in aqueous buffer solution of pH 4 to 6.5 and 
play a role in diseases such as mucocutaneous lymph 65 if desired, adding a polymeric binder. An oily formula-
node syndrome (Reiger et al., Eur. J. Pediatr. 140, pp tion for topical application is obtained by suspending 
92-97 (1983) and adult respiratory distress syndrome the compounds of Formula (I) or their pharmaceuti-
(Stockley, Clinical Science 64, pp 119-126 (1983); Lee cally acceptable salts in an oil, optionally with the addi-
17 
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tion of a swelling agent such as aluminum stearate and-
/or a surfactant. 
To use the above inhibitors in vitro, they are dis-
solved in an organic solvent such as dimethylsulfoxide 
or ethanol, and are added to an aqueous solution con- 5 
taining serine proteases. The final concentration of the 
organic solvent should be less than 25%. The inhibitors 
may also be added as solids or in suspension. The serine 
protease inhibitors of this invention would be useful in a 
variety of experimental procedures where proteolysis is 10 
a significant problem. Inclusion of these inhibitors in a 
radioimmunoassay experiments would result in higher 
sensitivity. The use of these inhibitors in plasma frac-
tionation procedures would result in higher yields of 
valuable plasma proteins and would make purification 15 
of the proteins easier. The inhibitors disclosed here 
could be used in cloning experi..-nents utilizing bacterial 
cultures, yeast and purified cloned product in higher 
yield. 
The following examples are given to illustrate the 20 
invention and are not intended to limit it in any manner. 
EXAMPLE 1 
Preparation of 
3-(2-Isothiureidoethoxy )-4-Chloroisocoumarin. 
2-Bromoethyl-2-carboxyphenylacetate was prepared 
from heating 10 g ofhomophthalic acid (56 mmole) and 
21 g of 2-bromoethanol (167 mmole) in 17 5 ml of ben-
zene with a few drops of cone. sulfuric acid at 90° -110° 
25 
C. for two hours, yield 64%. TLC shows that it is a pure 30 
compound. The cyclization of 2-bromoethyl 2-carbox-
yphenylacetate with PCls was performed by a previous 
method with modification (Tirodkar, and Usgaonkar, 
Indian. J. Chern. 7, pp 1114-1116 (1969)). 1.15 g of 
2-bromoethyl 2-carboxyphenylacetate was heated with 35 
2.1 g of PCls in 90 ml of benzene at 70° C. for 2 hrs. The 
benzene was removed and the residue triturated with 
petroleum ether. The crude product was purified by 
silica gel column chromatography with methylene 
chloride as an eluent to give 560 mg of 3-(brornoethyl)- 40 
4-chloroisocournarin (yield, 46% ). IR and NMR spectra 
show it was the desired product. 100 mg of 3-brornoeth-
yl-4-chloroisocournarin (0.3 rnmole) was heated with 60 
mg ofthiourea (0.8 rnrnole) in 5 ml ofTHF at 70° C. for 
2 days to give a yellow solid, 50 mg (yield, 40%), rn.p. 45 
167°-169° C. (dee); one spot on TLC, Rf=0.7 (Butanol-
:acetic acid:water=6:1:5); NMR spectrum (d6-DMSO), 
8 9.1 (2b, 4H), 7.5-8.1 (rn, 4H), 4.6 (t, 2H), 3.6 (t, 2H); 
mass spectrum (FAB+), rn/e=299 (M+-Br). Anal. 
Cale. for C12H12N203Br1ChS1: C, 37.96; H, 3.19; N, 50 
7.38. Found: C, 37.81; H, 3.28; N, 7.71. 
EXAMPLE2 
Preparation of 7-Guanidino-3-Methoxyisocournarin 
Methyl 2-carboxy-4-nitrophenyl acetate was pre- 55 
pared from 2-carboxy-4-nitrophenylacetate and metha-
nol by the procedure described above. Hydrogenation 
of this nitro compound gives methyl 4-amino-2-car-
boxy-phenylacetate (yield 90%). The guanidination of 
the amino compound with 3,5-dirnethylpyrazole-1-car- 60 
boxamidine nitrate (ADMP) was performed by a stan-
dard method described previously (Tsunematsu & 
Makismi, J. Biochem. 88, pp 1773-1783, (1980)). 2.2 g of 
amino compound (10 rnmole), 1.9 g oftriethylamine (19 
mmole) and 3.0 g of ADMP (15 mmole) was heated in 65 
20 ml ofTHF and refluxed for 18 hrs. The white precip-
itate was filtered and washed with cold methanol to 
give 1.5 g of methyl 2-carboxy-4-guanidinophenylace-
tate, (yield 46%). One spot on TLC, Rf=0.6 (Butanol:a-
cetic acid:pyridine:water=4:1:1:2), it shows an orange 
color when sprayed with Sakaguchi reagent. NMR 
spectrum (CF3COOH), 8 8.4, 7.7 (b, 4H), 6.6 (b, 4H) 4.4 
(s, 2H), 4.1 (s, 3H). Anal. Cale. for C11H13N304. i HiO: 
C, 50.77; H, 5.42; N, 16.15. Found: C, 51.03; H, 5.38; N, 
16.19. 0.9 g of methyl 2-carboxy-4-guanidinophenylace-
tate (3 nimole) was heated with 1.5 g of PCls (7.2 
rnmole) at 70°-80° C. for 2 hrs, white solid precipitated 
out during the heating. The solid was filtered off and 
purified by silica gel column chromatography with 
methylene chloride and methanol (5:1) as an·eluent to 
give 0.5 g of 7-guanidino-3-methoxyisocoumarin (yield 
59%). One spot on TLC, Rf=0.7 (Butanol:acetic acid:-
pyridine:water=4:1:1:2); m.p. 185°-186° C. (dee);, 
NMR spectrum (d6-DMSO): 8 7.9, 7.6 (b, 3H), 7.7 (b, 
4H), 6.1 (s, lH), 3.9 (s, 3H); mass spectrum (FAB+), 
m/e=234 (M+-CI). Anal. Cale. for C11H12N303Cl1. i 
H20: C, 47.40; H, 4.67; N, 15.08; Cl, 12.75. Found: C, 
47.42; H, 4.74; N, 15.05; Cl, 12.68. 
EXAMPLE3 
Preparation of 
7-Guanidino-3-Methoxy-4-Chloroisocournarin. 
0.27 g of 7-guanidino-3-methoxyisocoumarin (1 
rnmole) was chlorinated with 0.15 g ofN-chlorosuccini-
mide (1.1 mmole) in 5 ml DMF at r. t. overnight. The 
reaction mixture was evaporated to dryness, and puri-
fied oy silica gel column chromatography which is 
eluted with methylene chloride and methanol (5:1) to 
give 0.1 g of 7-guanidino-3-methoxy-4-chloroisocouma-
rin (yield 34%). One spot on TLC, Rf=0.75 (Butanol:a-
cetic acid:pyridine:water=4:1:1:2); NMR spectrum is 
similar to 7-guanidino-3-methoxyisocoumarin except no 
peak at 6.1 ppm; mass spectrum (FAB+), m/e=268 
(M+-CI). Anal. Cale. for C11H11N303C)i. i H20: C, 
42.17; H, 3.83; N, 13.41; Cl, 22.68. Found: C, 42.65; H, 
3.72; N, 13,28; Cl, 22.32. 
EXAMPLE4 
Preparation of 
7-Amino-4-Chloro-3-(3-Isothiureidopropox-
- y)isocoumarin. 
This compound was synthesized by the same proce-
dure as 3-(3-isothiureidopropoxy )-4-chloroisocournarin. 
3-Bromopropyl 2-carboxy-4-nitrophenylacetate was 
prepared from 2-carboxy-4-nitrophenylacetate and 3-
bromopropanol, yield 60%. Cyclization of the monoes-
ter with PCls gives 3-bromopropoxy-4-chloro-7-
nitroisocoumarin (yield, 60% ). Hydrogenation of the 
nitro compound (0.36 g) in methanol gives 0.12 g of 
7-amino-3-bromopropoxy-4-chloroisocoumarin, which 
is purified by silica gel column chromatography with 
methylene chloride as an eluent (yield, 36% ). This 
aminoisocoumarin reacts with thiourea in THF to give 
the final product, which can be crystallized from 
MeOH-ether (yield, 40%), mp 160°-162° C. (dee); one 
spot on TLC, Rf=0.6 (Butanol:acetic acid:pyridine 
water=_4:1:1:2); mass spectrum (FAB+), m/e=328 
(M+-Br). Anal. Cale. for C13H1sN303Cl1Br1S1: C, 
38.20; H, 3.70; N, 10.28; Cl, 8.67. Found: C, 38.15; H, 
3.73; N, 10.25; Cl, 8.63. 
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EXAMPLES EXAMPLE7 
Preparation of Preparation of 
7 ·(Alany !amino )-3-Methoxy-4-Chloroisocoumarin 7 ·(Acetylamino )-4-Chloro-3-(3-Isothiureidopropox-
Hydrochloride 5 y)isocoumarin 
7-(N-a-Boc-alanylamino)-3-methoxy-4• 7-Amino-3-(3-bromopropoxy)-4-chloroisocoumarin 
. . . . was synthesized as previously described (Kam et al., 
chloroisocoumann w~ synthe~ized by reaction o~B?c· 1988). This compound (0.33 g, 1 mmole) was heated 
Ala (1 g, 5.5 mmole) with 1,3-dicyclohexylcarbodumide with 0.15 g of acetic anhydride (1.5 mmole) in 20 ml of 
(0.57 g, 2.8 mmole) at 0° C. in THF for a few hours (DC 10 dry THF. After a few minutes, a yellow solid precipi-
Urea was precipitated out), followed by the addition of tated out. After 3 hrs, the solution was concentrated to 
7-amino-3-methoxy-4-chloroisocoumarin (0.5 g, 2.2 5 ml, and the solid was filtered to give 0.37 g of 7-
mmole). The reaction mixture was stirred at r. t. over- (acetylamino)-4-chloro-3-(3-bromopropoxy)isocouma-
night, and DC Urea was then filtered. The reaction 15 rin, m.p. 170°-172° C.; mass spectrum: m/e=375 (M+). 
mixture was evaporated to dryness, redissolved in The acetylated isocoumarin (0.15 g, 0.4 mmole) was 
CHiCband washed with 4% NaHco3. After evaporat- treated with thiourea (0.~36 g, 0.47 mmole) t? giv: 0.9 
ing the solvent, the residue was crysta1Iized in THF-Pet g of the final product, (yield 50%), m.p. 180 -181 C., 
. . . mass spectrum m/e=370 (M+-Br). Anal. Cale. for 
Ether to ~ve 0.2 ~· of .Boc-alanyhsocoumann com- 20 C1sH11N304CIBrS: C, 39.97; H, 3.80; N, 9.32; Cl 7.87. 
pound, which was 1dent1fied by NMR s~ectrum ~d Found: c, 39.S6; H 3.83; N, 9.29; Cl, 7.85. 
was shown ~ne spo~ on TLC. Boc-alanyhs~coumann 7-trifluoroacetylamino-4-chloro-3-(3-isothiureido-
(0.2 g) was stirred with 25 eq ofTFA (1.4 g) m CH2Cb propoxy)isocoumarin, 7-heptafluorobutyroylamino-4-
at r.t. for half hour and 1 eq of 3.8N HCl/dioxane was chloro-3-(3-isothiureidopropoxy)isocoumarin, 7-suc-
then added. The product was precipitated out when 25 cinylamino-4-chloro-3-(3-isothiureidopropox-
anhydrous ether was added, and was purified by col- y)isocoumarin, and 7-(o-phthalyl)amino-4-chloro-3-(3-
umn chromatography (CH2Clz: Me0H=7:1), yield 0.1 isothiureidopropoxy)isocoumarin can be prepared by 
g, one spot on TLC (CH2CI2: Me0H=7:1); NMR (d6- the same procedure. 
DMSO): 8 7.4-8.4 (m, 3H), 4.0 (s, 3H), 3.1-3.6 (m, lH), 
1.5 (d, 3H). 30 
EXAMPLE6 
Preparation of 
7-(Phenylcarbamoylamino)-4-Chloro-3-(2-Isothiureido- 35 
ethoxy)isocoumarin 
EXAMPLES 
Preparation of 
7 -(D-Phenylalanylamino )·4-Chloro-3-(2-Isothiureidoe-
thoxy )isocoumarin 
Boc-D-Phe (0.33 g, 1.2 mmole) reacted with 1,3-dicy-
clohexylcarbodiimide (0.13 g, 0.6 mmole) in 10 ml THF 
at 0° C. for 1 hr to form the symmetric anhydride, and 
7 -Amino-3-(2-bromoethoxy )-4-chloroisocoumarin then 7 -amino-4-chloro-3-(2-bromoethoxy )isocoumarin 
was synthesized as previously described (Powers et al., (0.2 g, 0.6 mmole) was added. The reaction was stirred 
Biochemistry 29, 3108-3118 (1990)). This compound at r. t. overnight and the precipitate 7-(Boc-D-Phe-
(0.32 g, 1 mmole) was mixed with phenyl isocyanate 40 amino)-4-chloro-3-(2-bromoethoxy)isocoumarin was 
(0.12 g, 1 mmole) in 5 ml ofTHF and the reaction mix- formed (0.29 g, 71%). TLC one spot, m.p. 180°-182° C.; 
ture was stirred at r.t. overnight. The product 7. mass spectrum m/e=566 (M+). Anal. Cale. for 
(phenylcarbamoylamino)-4-chloro-3-(2.bromoethox- C2sH26N206CIBr: C, 53.07; H, 4.63; N, 4.95; Cl 6.27. 
). · · · d . Id 40% Found: C, 53.25; H, 4.66; N, 4.87; Cl, 6.24. Boc-D-Phe y is?cou1!1ann precipitate out, y1e o, m.p. 45 compound (0.2 g, 0.35 mmole) was reacted with thio-
215 -217 C., mass spectrum m/e=437.9 (M+). Anal. urea (0.027 g, 0.35 mmole) in the same manner to give 
Cale. for C1sH14N204CIBr: C, 49.40; H, 3.22; N, 6.40; 7-(Boc-D-phenylalanylamino)-4-chloro-3-(2-isothi-
CI, 8.10. Found: C, 49.48; H, 3.25; N, 6.34; Cl, 8.12. The ureidoethoxy)isocoumarin (0.14 g), yield 62%, mass 
phenylcarbamoylamino compound (0.1 g, 0.23 mmole) spectrum (FAB+) m/e 561 (M+-Br). This compound 
was heated with 0.02 g of thiourea (0.26 mmole) in 10 50 (0.1 g) was dissolved in 3 ml of THF at 0° C. and then 
ml of THF at 70° C. overnight. The fmal product pre- the solvent was evaporated to dryness. The final prod-
cipitated out, yield 0.04 g, 36%, m.p. 161°-163° C. uct precipitated out after addition of ether, one spot 
(dee.), mass spectrum (FAB+) m/e=433 (M-Br). Anal. TLC (CH3CN:H20:Ac0H=8:1:1); mass spectrum 
Cale. for C19H1sN404CIBrS.0.25 THF: C, 45.12; H, 55 (FAB+) m/e 462 (M+-Br -CF3COO). 
3.86; N, 10.53; Cl, 6.67. Found: c, 44.83; H, 3.92; N, _7-Boc-al~ylamino-4-chlor~-3-(2-isothiureidoetho~-
10 12. Cl 6 41 y)isocoumarm, 7-benzoylammo-Ala-4-chloro-3-(2-iso-
. ' ' · · . . . . thiureidoethoxy)isocoumarin, 7-benzoylamino-Phe-4-
7 -(Et~ylcarbam~ylammo )-4-chloro-3-(2-isothi~reido- chloro-3-(2-isothiureidoethoxy )isocoumarin and 7 • Boc-
ethoxy )isoc~um~n,. 7 ·(t-b~tylcarb~oylammo )-4- 60 valylamino-4-chloro-3-(2-isothiureidoethoxy )isocouma-chloro-3-(2-isothiureidoethoxy )isocoumann, 7-(benzyl- rin can be prepared by the same procedure. 
thiocarbamoylamino)-4-chloro-3-(2-isothiureidoethox-
y)isocoumarin, 7 -( ethylthiocarbamoylamino )-4-chloro-
3-(2-isothiureidoethoxy)isocoumarin, 7 ·( 4-fluoroben-
zyl)thiocarbamoylamino-4-chloro-3-(2-isothiureidoe- 65 
thoxy)isocoumarin, and 7-(2,5-dimethylbenzyl)thiocar-
bamoylamino-4-chloro-3-(2-isothiureidoethox-
y)isocoumarin can be prepared by the same procedure. 
EXAMPLE9 
Preparation of 
7 -(m-Carboxyphenylthiocarbamoylamino )-4-Chloro-3-
(2-Isothiureidoethoxy )isocoumarin 
7 -(m-Carboxyphenylthiocarbamoylamino )-4-chloro-
3-(2-bromoethoxy )isocoumarin was prepared from the 
21 
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reaction of m-carboxyphenyl isothiocyanate with 7-
amino-4-chloro-3-(2-bromoethoxy )isocoumarin, yield 
64%, m.p. 157°-158° C.; mass spectrum m/e 361 (M+-
(COOH)PhNH+ I). Anal. Cale.: C, 45.85; H, 2.84. 
Found: C, 45.73; H, 2.86. The bromoethoxy compound 5 
was then reacted with thiourea to give the product, 
yield 21%; mass spectrum (FAB+) m/e 493 (M+-Br). 
EXAMPLE 10 
Preparation of 
7-Heptafluorobutyroylamino-4-Chloro-3-Methox-
yisocoumarin 
10 
7-Amino-4-chloro-3-methoxyisocoumarin (1 eq.) and 
heptafluorobutyryl chloride (1.5 eq.) were dissolved in 
THF and then EtJN (1.5 eq.) was added dropwise to the 15 
stirred mixture over a period of 4 h. After addition of 
Et3N was completed, the reaction mixture was stirred 
for 20 h at r.t., then the solvent was removed in vacuo 
and the residue dissolved in ethyl acetate. This solution 
was washed with water, 10% citric acid, 4% NaHC03 20 
and finally again with water, dried over MgS04 and 
evaporated. The residue was crystallized from THF-
hexane to give yellow solid; yield 62%; mp 189°-190° 
C.; MS, m/e 421 (M+). Anal. Cale. for C14li1F1ClN04: 
C, 39.84; H, 1.66; N, 3.32. Found: C, 40.24; H, 1.70; N, 25 
3.33. 
22 
acetate. After 30 min, the reaction mixture was evapo-
rated to dryness and the crude ester crystallized from 
acetone, giving a yellow solid, mp 147°-151° C. (dee.); 
MS m/e 353 (M+). Anal. Cale. for C16H16ClN06: C, 
54.30; H, 4.56; N, 3.96; Cl, 10.Q3. Found: C, 54.39; H, 
4.58; N, 3.39; Cl, 10.13. 
7-(methoxysuccinyl)amino-4-chloro-3-ethox-
yisocoumarin was prepared by the same procedure. 
EXAMPLE 13 
Preparation of 
7-[(N-Tosyl-a-phenylglycyl)amino ]-4-Chloro-3-
Methoxyisocoumarin 
N-Tosyl phenylglycine (1.8 mmole) was dissolved in 
2 ml of SOCl2 and stirred at reflux temperature for 40 
min. The reaction mixture was concentrated to dryness 
in vacuo and the residue triturated with EtOAc/Hex-
ane (3:1) to yield the acid chloride (94%) which is used 
in the next step without further purification. Tos-
phenylglycine acid chloride (155 mg) and 7-amino-4-
chloro-3-methoxyisocoumarin (72 mg) were dissolved 
in a mixture of methylene chloride (1 ml) and THF (1 
ml). A solution of triethylamine (0.06 ml in 2 ml of 
CH2Cli) was added dropwise and the reaction mixture 
was stirred at room temperature for 2 h. The solvent 
was removed in vacuo and the residue was triturated 
. 7-(3-fluor?benzoyl)amino-4-chloro-3-~ropox- with ethyl acetate (1.5 ml). The resulting yellow solid 
y1socoumann, 7-(4-methoxybenzoyl)ammo-4-chl~ro-3- was recrystallized from THF/H2o to yield 108 mg proI'oxyisocou~arin, 7-~eptafluorobutyroylammo-4- (66%)· m 150._151° c. (dee.)· MS m/e 512 (M+). 
chloro-3-ethoxy1socoumann, 7-hepta- 30 ' P ' ' 
fl b t 1 · 4 hi 3 (2 b th Anal. Cale. for C2sH21CIN206S: C, 58.53; H, 4.13; N, uoro u yroy ammo- -c oro- - - romoe ox- 5 46 F d· c 58 43. H 4 15· N 5 40 y)isocoumarin, 7-(3-fluorobenzoyl)amino-4-chloro-3-(2- · · oun · ' · ' ' · ' ' · · 
bromoethoxy)isocoumarin, 7-(3-nitrobenzoyl)amino-4- EXAMPLE 14 
chloro-3-(2-bromoethoxy)isocoumarin, 7-(a-toluenesul-
fonyl)amino-4-chloro-3-(2-bromoethoxy)isocoumarin 35 
can be prepared by the same procedure. 
EXAMPLE 11 
Preparation of 
7-(N-Pheny learbamoylamino )-4-Chloro-3-Methox-
yisocoumarin 
This compound was prepared by reaction of 110 mg 
(0.5 mmol) of 7-amino-4-chloro-3-methoxyisocoumarin Preparation of 
7-[(3-Phenylglutaryl)amino]-4-Chloro-3-Methox-
yisocoumarin 
40 with 60 mg (0.5 mmol) of phenyl isocyanate at room 
temperature in CH2Cli for 24 h. After standard work-
up, this isocoumarin was obtained as yellow crystals; 
mp 203°-204° C.; MS, m/e 344 (M+). Anal. Cale. for One gram of 7-amino-4-chloro-3-methoxyisocouma-rin dissolved in 15 ml of pyridine was treated with 4 
equivalents of 3-phenylglutaric anhydride. After 5 hr, 3 45 
ml of water were added to the reaction mixture. Partial 
evaporation of the solvents left a semisolid residue, 
which was diluted with a mixture of acetone and water 
(3:1), and filtered. The crude crystals were then recrys-
tallized from acetone/water to give yellow crystals, 50 yield 62%; mp 105°-106° C.; MS (FAB+) m/e 416 
(M+). Anal. Cale. for C21H1sClN06.!H20: C, 57.66; H, 
4.42; Cl, 3.20. Found: C, 57.60; H, 4.77; N, 3.17. 
C11H13ClN204: C, 59.23; H, 3.08; N, 8.13; Cl, 10.28. 
Found: C, 59.28; H, 3.82; N, 8.11; Cl, 10.35. 
7-benzylamino-4-chloro-3-ethoxyisocoumarin can be 
prepared by the same procedure. 
EXAMPLE 15 
Preparation of 
7-Phenylthiocarbamoylamino-4-Chloro-3-Ethox-
yisocoumarin 
This compound was prepared by reaction of7-amino-7-(o-phthalyl)amino-4-chloro-3-ethoxyisocoumarin 
can be prepared by the same procedure. 
EXAMPLE 12 
Preparation of 
7-[(Methoxyglutaryl)amino ]-4-Chloro-3-Methox-
yisocoumarin 
55 4-chloro-3-ethoxyisocoumarin with phenyl isothiocya-
nate at r. t. in THF for 24 hrs. The product was obtained 
as yellow solid: yield 55%, m.p. 176°-177° C. (dee.); 
TLC, Rp0.76 (CH3Cl:Me0H=9:1), MS m/e=374 
(M+). Anal. Calcd. for C1sH1sN203ClS: C, 57.62; H, 
60 4.00. Found: C, 57.77; H, 4.04. 
7-Glutarylamino-4-chloro-3-methoxyisocoumarin 
was prepared by the same procedure described in exam-
ple 2, mp 194° C. (dee.); MS m/e 339 (M+). Anal. Cale. 
for C1sH14ClN06.1.2 H20: C, 57.66; H, 4.42; N, 3.20. 
Found: C, 57.60; H, 4.77; N, 3.17. An ethereal solution 65 
containing 2.5 mmoles of diazomethane was added to a 
solution of 0.6 mmoles of 7-glutarylamino-4-chloro-3-
methoxyisocoumarin in a mixture of DMF and ethyl 
EXAMPLE 16 
Preparation of 
7-Dihydrocinnamoylamino-4-Chloro-3-Propylox-
yisocoumarin 
This compound was synthesized by reaction of equi-
molar of 7-amino-4-chloro-3-propoxyisocoumarin, 
dihydrocinnamic acid chloride and triethylamine in dry 
23 
5,324,648 
THF. The reaction mixture was stirred at r. t. over-
night, and the solution was washed with water, 4% 
NaHC03, water and dried over MgS04. After filtration 
and evaporation, a yellow residue was crystallized from 
THF-pentane, yield 81%; mp 182°-184° C.; TLC, s 
Rp0.74 (CH3Cl:Me0H=9:1); MS, m/e 385 (M+). 
Anal. Cale for C21H2004NCl.0.5H20: C, 63.81; H, 5.32. 
Found: C, 63.47; H, 5.30. 
7-phenoxycarbonylamino-4-chloro-3-ethox-
yisocoumarin can be prepared by the same procedure. 10 
EXAMPLE 17 
Preparation of 
7-(Boc-valyl)amino-4-Chloro-3-Propyloxyisocoumarin 
24 
(pheny learbamoylamino )-4-chloro-3-(2-bromoethox-
y)isocoumarin precipitated out, yield 40%, mp. 
215°-217° C.; MS, m/e 437.9 (M+). Anal. Cale. for 
C1sH14N204CIBr: C, 49.40; H, 3.22; N, 6.40; Cl, 8.10. 
Found: C,49.48; H, 3.25; N,6.34; Cl, 8.12. 
7-(4-Fluorobenzyl)thiocarbamoylamino-4-chloro-3-
(2-bromoethoxy)isocoumarin, and 7-(2,4-dimethylben-
zyl)thiocarbamoylamino-4-chloro-3-(2-bromoethox-
y)isocoumarin can be prepared by the same procedure. 
EXAMPLE21 
Preparation of 
7-(Boc-D-phenylalanylamino )-4-Chloro-3-(2-Bromoe-
thoxy )isocoumarin 
This compound was synthesized by reaction of an 15 Boc-D-Phe (0.33 g, 1.2 mmole) reacted with 1,3-dicy-
equimolar amount of 7-amino-4-chloro-3-propox- clohexylearbodiimide (0.13 g, 0.6 mmole) in 10 ml THF 
yisoc~mmar:ID and Boc-ya1 anhydride in 1:HF. The at o• C. for 1 hr to form symmetric anhydride, and then 
reaction muture was stirred at r. t. overrught. The 7 . -4- hi 3 (2 b th ). · (0 2 work-up as described above gives a yellow solid which -ammo c oro- - - romoe oxy. isocouma.nn · 
was recrystallized from THF-pentane, yield 48%: mp 20 g, 0.6 ~ole) was added. The react1~n was stirred at r. 
111·-173° C.; TLC, Rp0.8 (CH3Cl:Me0H=9:1); MS, t. overnight a~d 7-(Boc-~-phenyl~o)-4-chloro-3-(2-
m/e 452 (M+) Anal Cale for c H o N Cl· c 58 35. bromoethoxy)1socoumann was prec1p1tated out (0.29 g, 
. · . · · 
2~ 29 6 ~ . ' ." ' 71%), mp. 180°-182° C.; TLC, Rp0.95 H, 6.41, N, 6.19, Cl, 7.83. Found. C, 58.40, H, 6.47, N, (CH Cl·M OH- . )·MS _ 66 (M ) I Cal 6.20; Cl, 7.79. 3 . e -9.I , m/e-5 + . Ana. c. 
7-(Boc-phenylalanyl)amino-4-chloro-3-propylox- 25 for C2sH26N206CIBr: C, 53.07; H, 4.63; N, 4.95; Cl 6.27. 
yisocoumarin, 7-(benzoylalanylalanyl)amino-4-chloro- Found: C,53.25; H, 4.66; ~· 4.87; Cl, 6.24. 
3-propyloxyisocoumarin, 7-(Boc-valyl)amino-4-chloro- 7-(B~nzoyl-L-~anylammo )-4-chloro-3-(2-bromoe-
3-ethoxyisocoumarin and 7-(Boc-alanyl)amino-4- thoxy)1socoumann can be prepared by the same proce-
chloro-3-ethoxyisocoumarin can be prepared by the dure. . 
same procedure. 30 7-(D-Phenylalanylammo)-4-chloro-3-(2-bromoethox-
y)isocoumarin and 7-(alanylalanylamino )-4-chloro-3-(2-
bromoethoxy)isocoumarin can be prepared by deblock-
ing the Boe group of 7-(Boc-D-phenylalanylamino)-4-
chloro-3-(2-bromoethoxy)isocoumarin and 7-(Boc-D-
EXAMPLE 18 
Preparation of 
7-Ethylearbamoylamino-4-Chloro-3-Propylox-
yisocoumarin 35 alanylalanylamino )-4-chloro-3-(2-bromoethox-
This compound was synthesized by the reaction of an 
equimolar amount of 7-amino-4-chloro-3-propox-
yisocoumarin and ethyl isocyanate in small amount of 
dry THF. The reaction mixture was stirred at r. t. for a 
few days. During this time the yellow crystals slowly 40 
crystallized out. After filtration, the compoumds were 
recrystallized once more from THF-pentane, yield 
45%; mp 189°-191° C.; TLC, Rp0.43 
(CH3Cl:Me0H=9:1); MS, m/e 324 (M+). Anal. Cale. 
for C1sH1104N2Cl: C, 55.42; H, 5.23. Found: C, 55.31; 45 
H, 5.28. 
EXAMPLE 19 
y )isocoumarin with trifluoroacetic acid. 
EXAMPLE 22 
Preparation of 
7-Dansylamino-4-Chloro-3-(2-Bromoethoxy )isocouma-
rin 
Dansyl chloride (0.17 g, 0.63 mmole) was mixed with 
7-amino-4-chloro-3-(2-bromoethoxy)isocoumarin (0.2 
g, 0.63 mmole) in 5 ml ofTHF, and Et3N (0.065 g) was 
then added. The reaction mixture was stirred at r. t. for 
a few days, and a yellow solid was precipitated out. The 
final product was crystallized from THF /hexane, yield 
41%, mp 114°-117° C.; MS, m/e 552 (M++l). Anal. 
Preparation of 
7-Amino-4-Chloro-3-(2-Bromoethoxy)isocoumarin 50 
Cale. for C23H21N20sC1BrS.1.SH20: C, 47.63; H, 4.14. 
Found: C, 47.41; H, 4.27. 
7-(p-Toluenesulfonyl)amino-4-chloro-3-(2-bromoe-
thoxy )isocoumarin can be prepared by the same proce-
dure. 
This compound was prepared by cyclization of 1 
equivalent of bromoethyl nitrohomophthalate with 2.5 
equivalent of PCls, followed by catalytic reduction of 
the nitro group. The product was yellow solid, mp 55 134°-137° C.; MS, m/e 317 (M+). Anal. Cale. for 
C11H9N03CIBr: C, 41.44; H, 2.83, N, 4.40. Found: C, 
42.11; H, 2.87; N, 4.46. 
EXAMPLE20 
EXAMPLE23 
Preparation of 
7-(Biotinylamino )-4-Chloro-3-(2-Phenylethox-
y )isocoumarin 
Preparation of 
7-(Phenylearbamoylamino)-4-Chloro-3-(2-Bromoe-
thoxy )isocoumarin 
60 Biotin acid chloride was prepared by incubating 0.4 g 
7-Amino-3-(2-bromoethoxy)-4-chloroisocoumarin 
was synthesized as described above. This compound 65 
(0.32 g, 1 mmole) was mixed with phenylisocyanate 
(0.12 g, 1 mmole) in 5 ml ofTHF and the reaction mix-
ture was stirred at r. t. overnight. The product 7-
of biotin in 6 ml of thionyl chloride at 25° -35° C. for 1 
hr, and excess thionyl chloride was removed under 
vacuum. The acid chloride was used for the next step 
without further purification. Biotin acid chloride and 
7-amino-4-chloro-3-(2-phenylethoxy)isocoumarin (0.26 
g) was dissolved in small amount of DMF, and then 
Et3N (0.08 g) were added. The reaction mixture was 
stirred at r. t. overnight. The product was purified by 
25 
5,324,648 
26 
column chromatography, yield 0.1 g, mp 182°-185° C.; 
TLC, Rp0.25 (CH2Cli:MeOH= 15:1). Anal. Cale for 
C21H28N305CJS.0.25H20: C, 59.39; H, 5.22, N, 7.70. 
Found: C, 59.08; H, 5.37; N, 7.94. 
Cell Res. 100, pp 213-217 (1976)) and methyl 6-
aminocaproic acid hydrochloride by a previously de-
scribed method (Hoffmann et al., Biochemistry 23, pp 
2547-2553 (1984)). 6-(Biotinylamino)caproic acid chlo-
7-(Biotinylamino )-4-chloro-3-(pentafluoropropox-
y )isocoumarin can be prepared by the same procedure. 
EXAMPLE24 
5 ride was synthesized and reacted with 7-amino-4-
chloro-3-(2-phenylethoxy)isocoumarin as described 
above. The product was purified by column chroma-
tography, - mp 163°-167° C. Anal. Cale. for 
Preparation of C33H39N406CIS.H20: C, 58.72; H, 6.22; N, 8.96; Cl, 
7-[(6-Biotinylamino)caproyl]amino-4-Chloro-3-(2- 10 5.59. Found: C, 58.87; H, 6.14; N, 8.32; Cl, 5.27. 
TABLE I 
Inactivation Rates for Inhibition of TEl'.)1sin-Like Serine Proteases b:z: Substituted Isocoumarins0 
W[IJ (M-ls-1) 
human porcine human human human 
bovine bovine factor pancreatic plasma human factor bovine factor 
Inhibitors thrombinb factor xac Xad kallikrein• kallikrein8 factor Xla8 XII ah trypsin; vuai 
3-(3-aminopropoxy )- 3.0 Nik 5.0 30 30 3.0 1,200 
isocoumarin 
3-(3-aminopropoxy)- 350 160 860 1,400 380 190 7,600 
4-chloroisocoumarin 
3-(2-isothiureidoethoxy)- 4,700 S,600 12,000 280,oooI 44,000 39,000 32,000 
4-chloroisocoumarin 
3-(3-isothiureidopropoxy)- 1,430 220 19,000 >110,0001 47,000 27,000 46,000 450 
4-chloroisocoumarin 
7-amino-3-(3-iso- 630 1,640 60 > 110,ooom 1,100 22,000 6,200 410,000" 430 
thiureidopropoxy)-4-
chloroisocoumarin 
7-guanidino-3-methoxy- 4,900 460 1,900 13,000 1,400 S20 3,300 
isocoumarin 
7-guanidino-3-methoxy- 290,000" 3,100 11,000 45,000" 240,000" 36,200 20,000 310,000" 
4-chloroisocoumarin 
7-guanidino-3-ethoxy- 3,700 2,700 16,000 44,000 3,100 1,300 20,000 
isocoumarin 
7-guanidino-3-ethoxy- >Ss,ooom 26,700 11,000 >200,ooom >SOO,oool 60,000 22,000 >llO,ooom 2,200 
4-chloroisocoumarin 
7-guanidino-3-(2-phenyl- S,700 11,000 16,000 62,000 1,200 690 45,000 
ethoxy)isocoumarin 
7-guanidino-3-(2-phenyl- >30,ooom 96,000 11,000 200,ooom >270,000/ 20,000 26,000 > 110,ooom 
ethoxy)-4-chloro-
isocoumarin 
7-(glycylamino)-3-methoxy- Sl.5 NI 32,100 
4-chloroisocoumarin 
7-(alanylamino )-3-methoxy- NI NI 470 
4-chloroisocoumarin 
"Conditions were as 0.lM Hepes, O.OIM CaCl2. pH 7.5 and 8-12% Me2SO and 25' C. Rate constants were measured by incubation method unless otherwise noted. An 
aliquot of inhibitor was added to an enzyme solution and aliquots removed with time and assayed for remaining enzymatic activity. First-order rate constants, le.obs were 
obtained from the plots of ln(v,lv0) versus time. 
"inhibitor concentrations were from 0.3 to 400 JLM. 
'Inhibitor concentrations were from 0.4 to 310 µM. 
dJnhibitor concentrations were from S tO 105 µ.M. 
'Inhibitor concentrations were from 0.4 to 300 µM. 
IJ:nhibitor concentrations were from 0.3 to 300 µM. 
'Inhibitor concentrations were from 3 to 330 µM. 
"inhibitor concentrations were from 3 to 330 µM. 
~nhibitor concentrations were from I to 12 µM . 
.IJ.nhibitor concentrations were from S to 44 µM. 
~o inhibition. 
'inactivation was extremely rapid, and the koWTI] values were based on the residual enzymatic activity at 0.2 min. 
'"Second-order rate constant was obtained from same concentration of enzyme and inhibitor. 
"Inactivation rate constants were obtained by progress curve method described by Tian and Tsou, Biochemistry 21, 1028-1032 (1982). 
Phenylethoxy)isocoumarin 
6-(Biotinylamino)caproic acid was prepared from 
N-hydroxysuccinimido biotinate (Jasiewicz et al., Exp. 
TABLE II 
Inactivation Rates of Inhibition 
of Complement Proteins b:z: Substituted lsocoumarins and APMSP. 
k,,i,,/[1) (M-ls-1) 
Inhibitors 
APMSF 
3,4-dichloroisocoumarin 
3-ethoxy-4-chloroisocoumarin 
7-amino-3-methoxy-4-chloroisocoumarin 
3-(2-isothiureidoethoxy )-4-chloroisocoumarin 
3-(3-isothiureidopropoxy)-4-chloroisocoumarin 
7-amino-3-(3-isothiureidopropoxy)-4-chloroisocoumarin 
7-guanidino-3-methoxy-4-chloroisocoumarin 
7-guanidino-3-ethoxy-4-chloroisocoumarin 
110 
192 
0.25 
1.3 
61 
145 
55 
252 
193 
NI8 
NI 
NI 
NI 
1.5 
0.5 
NI 
NI 
NI 
NI NI NI 
NI NI NI 
NI NI NI 
NI NI NI 
1.4 13 15 
0.8 0.4 0.8 
285 
167 
NI 
74 
95 
c1;e c1i/ 
170 42 
130,000 6,610 
23,000 1,320 
660 75 
690 239 
27 
5,324,648 
28 
TABLE II-continued 
Inactivation Rates of Inhibition 
of Complement Proteins by Substituted Isocoumarins and APMSF". 
kek,!lIJ (M-ls- 1) 
Inhibitors Cir! 
7-guanidino-3-(2-phenylethoxy)-4-chloroisocoumarin 92 NI S8 90 342 
"Conditions were O.lM Hepes, O.SM NaCl, pH 7.S, 8-10% Me2SO and 2S' C. Inactivation rates were measu[ed by incubati9n method. 
Enzyme concentrations were as follows: protein D, 1-9 l'M; Cl, 0.7-1 l'M; B, 1.8 l'M; Bb, 0.3-0.8 l'M; Cls, 0.07 l'M; Cir, O.Sl l'M. 
6lnhibitor concentrations were from 0.0S mM to 1.29 mM. 
'Inhibitor concentrations were from 0.19 mM to 1.2S mM. 
"inhibitor concentrations were from O.OS mM to 1.2S mM. 
'Inhibitor concentrations were from 0.8 l'M to 44 l'M . 
.!inhibitor concentrations were from 4.6 l'M to 470 l'M· 
'No inhibition. 
TABLE III 
The Inactivation Rates of Sheep Lun~ Lymph Tryptase0 , 
Human Lung Tryptase0 and Rat Skin Tryptase by Substituted Isocoumarins. 
k@,l[l] (M-15-1) 
Inhibitors S.L. Tryptase< H.L. Tryptased R.S. Tryptase' 
3,4-dichloroisocoumarin 
3-(3-aminopropoxy)isocoumarin 
3-(3-aminopropoxy)-4-chloroisocoumarin 
3-(2-isothiureidoethoxy)-4-chloroisocoumarin 
3-(3-isothiureidopropoxy)-4-chloroisocoumarin 
7-amino-3-(3-isothiureidopropoxy)-4-chloroisocoumarin 
7-guanidino-3-methoxyisocoumarin 
7-guanidino-3-methoxy-4-chloroisocoumarin 
7-guanidino-3-ethoxyisocoumarin 
7-guanidino-3-ethoxy-4-chloroisocoumarin 
7-guanidino·3·(2·phenylethoxy)isocoumarin 
7-guanidino-3-(2-phenylethoxy)-4-chloroisocoumarin 
APMSFf 
39 
8.1 
18 
290 
230 
710 
53 
620 
ISO 
2,200 
ISO 
3,900 
230 
18S 610 
2,000 8,370 
64,000 53,000 
28,000 63,000 
20,000 S2,000 
61,000 82,000 
S6,000 86,000 
"Inactivation rates were measured at O.IM Hepes, 0.5M NaCl, pH 7.5 buffer, 8% Me2SO and 25' C. 
6lnactivation rates were measured at 25 mM phosphate. 0.5M NaCl, 1 mM EDTA, pH 7.S buffer, 9% Me2SO and 2S' C. 
'Inhibitor concentrations were from 10 l'M to 460 l'M· 
dlnhibitor concentrations were from 0.4 l'M to 50 l'M. 
'"Inhibitor concentrations were from 0.4 µ.M to 50 µM. 
frhe inhibition rate was measured at 0.IM Hepes, 0.5M NaCl, pH 7.0, 25' C. 
TABLE IV 
Inactivation Rates for Inhibition of Serine Proteases by Substituted Isocoumarins0 
kek,/lIJ (M- ls- l) 
Inhibitors PPEk HLE< Chymotrypsind Cathepsin G' 
3-(3-aminopropoxy)isocoumarin 
3-(3-aminopropoxy)-4-chloroisocoumarin 
3-(2-isothiureidoethoxy)-4-chloroisocoumarin 
3-(3-isothiureidopropoxy)-4-chloroisocoumarin 
7-amino-3-(3-isothiureidopropoxy)-4-chloroisocoumarin 
7-guanidino-3-methoxyisocoumarin 
7-guanidino-3-methoxy-4-chloroisocoumarin 
7-guanidino-3-ethoxyisocoumarin 
7-guanidino-3-ethoxy-4-chloroisocoumarin 
7-guanidino·3·(2·phenylethoxy)isocoumarin 
7-guanidino-3·(2-phenylethoxy)-4-chloroioscoumarin 
7-(glycylamino)-3-methoxy-4-chloroisocoumarin 
7-(alanylamino)-3-methoxy-4-chloroisocoumarin 
2.3 
70 
270 
70 
1.0 
SS 
860 
86 
2,300 
Nih 
5.7 
1,960 
1,610 
47 
860 
220 
2,000 
130 
320 
6,400 
1,900 
81,000 
0.9 
73 
7,710 
13,500 
38 
S80 
1,300 
1,700 
1,600 
270 
7,200 
990 
37,000 
2,600 
38,000 
2.8 
260 
110 
83 
36 
_f 
11,000 
_g 
84,000 
i 
66,000 
4.9 
20 
"Inactivation rates were measured at O.lM Hcpcs, O.S NaCl, pH 7.S, 8-12% MeiSO and 25' C. by incubation method. An aliquot of inhibitor was 
added to a solution of enzyme and aliquots removed with time and assayed for remaining activity. 
6lnhibitor concentrations were from O.Ql to 0.Sl mM. 
'Inhibitor concentrations were from 0.001 to 0.18 mM. 
"inhibitor concentrations were from 0.004 to 0.33 mM. 
'Inhibitor concentrations were from 0.002 to 0.3S mM . 
.!inhibition was not time dependent, 81% inhibition was obtained at 0.49 mM. 
'Inhibition was not time dependent, 87% inhibition was obtained at 47 l'M. 
"No inhibition. 
iinhibition was not time dependent, 87% inhibition was obtained at O.S3 mM. 
Inhibitors 
7-guanidino· 
3-ethoxy-4-
TABLE V 
Inactivation Rates for Inhibition of Chymases 
by Substituted Isocoumarins0 • 
Rat Mast Cell 
Protease II h 
1100 
Human Skin Human Lung 
Chymase< Chymased 
33 540 
65 
Inhibitors 
TABLE V-continued 
Inactivation Rates for Inhibition of Chymases 
by Substituted Isocoumarins0 • 
Rat Mast Cell 
Protease II h 
Human Skin Human Lung 
Chymase< Chymased 
chloroisocoumarin 
7-guanidino-3-(2· 4100 22 
29 
5,324,648 
30 
TABLE VII TABLE V-continued 
Inactivation Rates for Inhibition of Chymases 
by Substituted Isocoumarins•. 
Inhibitors 
phenylethoxy)-4-
chloroisocoumarin 
Rat Mast Cell Human Skin Human Lung 
Protease Ilb Chymasec Chymased 
5 
"Inactivation rates were measured at O.IM Hcpcs, 0.SM NaCl, pH 7.5, 8-12% 
MezSO aod 25' C. by incubation method. An aliquot of inhibitor was added to a 10 
solution of enzyme and aliquots were removed with time and assayed for the 
remaining activity. 
binbibitor concentration were from 0.007 mM to 0.013 mM. 
<J.nlubitor concentration were from 0.41 mM to 0.53 mM. 
"inhibitor concentration was 0.38 mM. 
TABLE VI 
Inactivation of Human Plasmin and Recombinant Human 
Tissue Plasminogen Activator by Substituted Isocoumarins0 • 
Plasrninb 
Plasminogen 
Inhibitor Activatorc 
3,4-dichloroisocoumarin 73 
3-(3-aminopropoxy )isocoumarin 36 
3-(3-aminopropoxy)-4-chloro- 770 94 
isocoumarin 
3-(3-isothiureidopropoxy)-4-chloro- 4,690 
isocoumarin 
7-amino-3-(3-isothiureido- 4,340 S,690 
propoxy)-4-chloroisocoumarin 
7-guanidino-3-methoxyisocoumarin 320 
3,SOO 4,420 
15 
20 
25 
Inactivation Rates of Mouse Granzyme A, Human Granzyme A 
and Q-31 Tryptase by Substituted Isocoumarins•. 
Mouse Human Human Q-31 
Inhibitors Granzyme Ab Granzyme Ab Tryptasec 
3,4-dichloro- so so 29 
isocoumarin 
3-(3-arninopropoxy)- 770 2,010 
4-chloro-
isocoumarin 
3-(3-isothiureido- 17,SOO 18,420 12,830 
propoxy)-4-
chloro-
isocoumarin 
7-arnino-3- 3,000 6,750 1,960 
(3-isothiureido-
propoxy)-4-
chloroisocoumarin 
7-guanidino-3- lS,000 6,620 
methoxy-4-
chloro-
isocoumarin 
7-guanidino-3- 26,200 6,850 6,180 
ethoxy-
4-chloro-
isocoumarin 
7-guanidino-3- 6,400 1,880 
(2-phenylethoxy)-
4-chloro-
isocoumarin 
7-guanidino-3-methoxy-4-chloro-
isocoumarin 
"Inactivation rates were measured at O.!M He!'C'. O.O!M CaClz, pH 7.5, 8% MezSO 
aod 25' C. by incubation method. Z-Arg-SBzl (74-85 f.LM) was used as the substrate 
to monitor the residual enzymatic activity. 
30 l>inhibitor concentrations were from 0.4 ,.M to 45 ,.M. 
7-guanidino-3-ethoxy-4-chloro- 12,320 7,720 "Inhibitor concentrations were from 3 µ.M to 500 JLM. 
isocoumarin 
7-guanidino-3-(2-phenylethoxy)-4- 4,140 6,780 
chloroisocoumarin 
7-(glycylamino)-3-methoxy- 1,470 
4-chloroisocoumarin 
7-(alanylamino )-3-methoxy- 31 
4-chloroisocoumarin 
"Inactivation constants were measured at O. !M He!'C', 0.5M NaCl (or 0.0!M CaClz), 
pH 7.5, 8-12% MezSO and 25' C. 
°Inhibitor concentrations were from 4 µM to 330 µM. 
cinhibitor concentrations were from 7 µM to 44 µM. 
TABLE VIII 
Inhibition Rates of Bovine Trypsin and Coagulation 
Enzymes by 7-Substituted4-chloro-3-isothiureidoalkoxyisocoumarins0 • 
kob,/fIJ (M- 1s- 1) 
Bovine Bovine Human Human 
Factor Xa' 
Human Human 
Compounds Trypsinb Thrombinc Thrombind Factor Xlaf Factor XIIaK 
NH2-CiTPrOIC 410,oooh 63oh 760 22.oooh 6,2ooh 
PhCH2NHCONH-CiTPrOIC 51,000 420 700 
PhNHCONH-CiTPrOIC 63,000 970 1,840 50 7,720 
CH3CONH-CiTPrOIC 107,000 420 310 
PhCH2CH2CONH-CiTPrOIC 87,900 820 630 
PhCH2CONH-CiTPrOIC 16S,000 600 610 
L-Phe-NH-CiTPrOIC 400 470 
Boc-L-Phe-NH-CiTPrOIC 330 520 
D-Phe-NH-CiTPrOIC 68,300 180 220 
Boc-D-Phe-NH-CiTPrOIC 105,000 190 230 
Ph-NH-CO-NH-CiTEtOIC 21,000 25,000 22,400 4,740 104,000 50,000 
PhCH2NHCONH-CiTEtOIC 16,800 11,680 2,340 105,000 45,000 
PhCH2CONH-CiTEtOIC 15,800 6,730 3,630 59,000 
D-Phe-NH-CiTEtOIC 4,240 3,070 3,070 82,000 
Boc-D-Phe-NH-CiTEtOIC 1,040 1,090 
L-Phe-NH-CiTEtOIC 1,280 1,340 3,770 107,000 
Boc-L-Phe-NH-CiTEtOIC 1,090 1,140 1,620 
Ala-Ala-NH-CiTEtOIC 1,070 880 1,490 
Boc-Ala-Ala-NH-CiTEtOIC 1,530 970 
(CH3)2CHNHCONH-CiTEtOIC 4,100 5,000 
Naphthyl-NHCONH-CiTEtOIC 17,500 S,800 
S-C6lf5(CH3)CHNHCONH-CiTEtOIC 41,300 21,000 
R-C6lf5(CH3)CHNHCONH-CiTEtOIC 29,500 12,000 
PhNHCSNH-CiTEtOIC 21,400 
5,324,648 
31 
TABLE VIII-continued 
Inhibition Rates of Bovine Trypsin and Coagulation 
Enzymes by 7-Substituted-4-chloro-3-isothiureidoalkoxyisocoumarins•. 
32 
Bovine 
Trypsinb 
Bovine 
Thrombin< 
Human Human Human Human 
Compounds Thrombind Factor Xa' Factor Xlaf Factor Xllag 
m-Carboxy-PhNHCSNH-CiTEtOIC 17,500 
"Inhibition rates were measured in O.IM Hepes. O.OIM CaCl2. pH 7.5 buffer, 8% MeiSO and at 25' C. 
6Inhibitor concentration were 1.1-4.6 µM. 
"Inhibitor concentration were 1.2-54 µM. 
'Inhibitor concentration were 1.2-54 µM. 
'Inhibitor concentration were 3.6-44 µM. 
!inhibitor concentration were 0.7-0.8 µM. 
'Inhibitor concentration were 3.6-4.9 µM. 
"Data was obtained from Kam, Fujikawa, and Powers Biochemistry 27, pp 2547-2557.(1988). 
TABLE IX 
Inhibition of Severlll T!)'.Etases b:z: 7-Substituted-4-chloro-3-isothiureidoalkoxyisocoumarins•. 
~bsl[!] (M-ls-1~ 
Human Skin Rat Skin Human Lung Human Human 
Compounds Tryptaseb Tryptase< Tryptased Plasmin' r-t-PAf 
NH2-CiTPrOIC 39,000 19,000 13,000 
PhCH2NHCONH-CiTPrOIC 68%g 270,000 190,000 5,120 18,000 
PhNHCONH-CiTPrOIC 38,000 250,000 140,000 19,000 
CH3CONH-CiTPrOIC 99,000 60% 7,000 
PhCH2CH2CONH-CiTPrOIC 170,000 180,000 15,000 
PhCH2CONH-CiTPrOIC 145,000 140,000 9,000 
L-Phe-NH-CiTPrOIC 96,000 54% 11,000 
Boc-L-Phe-NH-CiTPrOIC 150,000 170,000 6,000 
PhNHCONH-CiTEtOIC 170,000 170,000 32,000 16,000 
PhCH2NHCONH-CiTEtOIC 200,000 280,000 19,000 
PhCH2CONH-CiTEtOIC 120,000 110,000 64%g 
D-Phe-NH-CiTEtOIC 62,000 360,000 60,000 15,000 
Boc-D-Phe-NH-CiTEtOIC 135,000 44%g 65%g 
L-Phe-NH-CiTEtOIC 650,000 260,000 13,000 
S-C6Hs(CH3)CHNHCONH-CiTEtOIC 27,800 
"Inhibition rates were measured in 0. IM Hepes, O.OIM CaCl2. pH 7.5 buffer for human plasmin; 25 mM Phosphate, 0.SM NaCl, 
I mM EDTA, pH 7.5 buffer for rat skin tryptase and O.IM Hepes, O.SM NaCl, pH 7.5 for human lung tryptase, human skin 
tryptase and r+PA. All enzymes were assayed with Z-Arg-SBzl (0.07 mM) in the presence of 4,4' -dithiodipyridine (0.33 mM). 
Reaction mixtures contained 8% Me2SO and assays were performed at 25• C. 
binhibitor concentrations were 0.34-0.39 µM. 
"Inhibitor concentrations were 0.42-0.S 1 µM 
dlnhibitor concentrations were 0.42-0.47 µM. 
~nhibitor concentrations were 8.3-41 µM. 
/inhibitor concentrations were 3.5-S.O µM, r-t-PA = recombinant-tissue plasminogen activator. 
'Inhibition was not time dependent and the percentage was measured at 0.34-5.0 µM. 
TABLEX 
Inhibition of Serine Proteases by 7-Substituted-4-chloro-3-isothiureidoalkox:z:!socoumarins0 . 
~1zi[I] (M-ls-1~ 
Compounds PPEb HLEC Chymotrypsind Cathepsin ab 
PhCH2NHCONH-CiTPrOIC 9%' 250 13,430 50 
CH3CONH-CiTPrOIC NV 200 5,200 31 
PhCH2CONH-CiTPrOIC NI 130 260,ooog 64 
PhNHCONH-CiTEtOIC 840 46,oooh 16,000 100 
5,730 
Boc-D-Phe-NH-CiTEtOIC 12'7.I 3,100 220 35 
L-Phe-NH-CiTEtOIC NI NI 8,400 53 
S-C6ff5(CH3)CHNHCONH-CiTEtOIC 21'7.I 5,looh 260 35 
360 
R-C6ff5(CH3)CHNHCONH-CiTEtOIC 9o/.I 40%; 360 145 
"Inhibition rates were measured in O. IM Hepes, 0.05M NaCl, pH 7.5 buffer, 8-9% MeiSO and at 25' C. Substrates 
were Sue-Ala-Ala-Ala-NA (0.48 mM) for PPE; MeO-Suc-Ala-Ala-Pro-Val-NA (0.24 mM) for 
HLE; Suc-Val-Pro-Phe-NA (0.48 mM) for chymotrypsin and cathepsin G. 
bJnhibitor concentrations were 33-46 µM. 
'Inhibitor concentrations were 2.1-42 µM. 
<linhibitor concentrations were 0.9-43 µM. 
'Percentage of inhibition was obtained after 20 min incubation of enzyme with inhibitor . 
.!No inhibition. 
•Second order of rate constant was obtained at equaJ molar concentrations of enzyme and inhibitor. 
"inhibition was biphasic. 
ipercentage of inhibition was obtained after 5 min incubation of enzyme with inhibitor. 
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TABLE XI 
Inhibition Constants for Inactivation of Elastases by 
7-substituted-4-chloro-3-alkox~socoumarins0• 
HLE PPE 
Compounds [I] kobsl[I] [I] kobsl[I] 
7-Substituent (µM) (M-ls-1) (µM) (M-18-1) 
7-substituted-4-chloro-3-methox:z:isocoumarin 
NCO 1.8 9,200 8.3 650 
EtOCONH 2.3 47,000 8.3 2,000 
PhOCONH 1.8 13,000 8.8 850 
PhCH20CONH 1.6 71,000 136.0 260 
H2NCONH 8.2 2,100 
CH3NHCONH 3.3 9,460 13 1,300 
EtNHCONH 6.3 1,700 
i-PrNHCONH 3.0 9,000 12 2,300 
i-BuNHCONH 6.6 20,000 13 3,200 
PhNHCONH 2.0 49,000 8.3 7,300 
PhCH2(PhCH2CH2)NCONH 2.2 12,000 490.0 17 
C3F7CONH 2.7 47,000 17.0 1,100 
Fmoc-NH 2.5 10,000 600.0 20 
Tos-Phenylglycyl-NH 1.6 84,000 8.3 1,500 
o-HOOCC614CONH 1.8 52,000 17.0 2,700 
o-CH300CC6ff4CONH 8.3 7,100 
CH300CCH2CH2CONH 2.3 43,000 17.0 2,200 
CH300CCH2CH2CH2CONH 2.3 54,000 8.3 2,800 
HOOCCH2CH(Ph)CH2CONH 1.6 66,000 8.3 3,100 
m-CH300CNHC614CONH 1.4 100,000 17.0 2,500 
7-substituted-4-chloro-3-ethox~socoumarin 
EtO-CO-NH 9.6 3,500 
Et-NH-CS-NH 20-50 4,200 
Ph-NH-CS-NH 9-31 12,000 
•inhibition constants were in O.IM Hepes, 0.5M NaCl, pH 7.5 buffer, 8-9% Me2SO and at 25" C. 
TABLE XII 
Inhibition Rates of Inactivation of Serine Proteases by Derivatives 
of 7-Substituted-4-chloro-3-propyloxyisocoumarins0 . 
Compounds 
7-Substituent 
PhCH2CH2CONH 
CH3CH20CONH 
CH3CH2NHCONH 
PhNHCONH 
PHNHCSNH 
PhCH2NHCSNH 
3-N02-C6ff4CONH 
CH3SCH2CONH 
Boe-Val-NH 
220 
1,600 
80 
520 
HLEC 
>250,000 
>181,000 
>276,000 
143,000 
> 166,000 
>131,000 
>210,000 
> 152,000 
64,000 
Chymotrypsind Cathepsin G' 
12,000 
5,200 
120 
6,100 
20 
138 
166 
NJ 
4 
28 
17 
"Inhibition rates were measured in O.lM Hepes, 0.5M NaCl, 2.5% Me2SO, pH 7,5 and at 25' C. 
61.nhibitor concentrations were 34-56 µ.M. 
CJnhibitor concentrations were 0.7-1.9 µM. 
dlnhibitor concentrations were 3.4-70 µM. 
-inhibitor concentrations were 8.7-87 µM. 
TABLE XIII 
Inhibition of Serine Proteases by Biotin-Isocoumarin Derivates0 • 
Compounds Chymotrypsinb Cat. Ge HLEd 
330 NI 740 
165 
PPE' 
NI 7-biotinylamino-4-chloro-
3-2(2-phenylethoxy)isocoumarin 
7-biotinylamino-4-chloro-
3-propoxyisocoumarin 
65 6.7 19,900 470 
7-( 6-biotiny laminocaproy l)amino-4-chloro-
3-(2-phenylethoxy)isocoumarin 
7-( 6-biotinylaminocaproyl)amino-
4-chloro-3-propoxyisocoumarin 
7-(6-biotinylaminocaproyl)amino-
4-chloro-3-ethoxyisocoumarin 
1,080 
190 
260 
260 
13% 
3.3 
59 
670 
76,700 
96,000 
NV 
350 
520 
"Inhibition WIS measured in O.IM Hepes, 0.5M NaCl, pH 7.5 buffer, 5-10% Me2SO and at 25' C. Suc-Val-
Pro-Phe-NA (0.48 mM) WIS used IS the substrate for chymotrypsin and cat G. MeO-Suc-Ala-Ala-
Pro-Val-NA (0.2'4-0.47 mM) and Sue-Ala-Ala-Ala-NA (0.29-0.48 mM) were used as the substrate for 
HLE and PPE respectively. 
6lnhibitor concentrations were 20-400 µM. 
'Inhibitor concentrations were 75-400 µM. 
'inhibitor concentrations were 2.0-78 µM. 
"Inhibitor concentrations were 38-78 µM . 
.INo inhibition. 
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TABLE XIV 
Inhibition of Rat granule Serine Proteases by Biotin-lsocoumarin Derivatives•. 
[I) Rat Granule Chymase Rat Granule Tryptase 
Compounds (mM) % of inhibitionb kobsf[I) (M- ls-1) 
7-(6-Biotinylaminocaproyl)amino-4-chloro- O.Q78 30-50 6-12 
3-(2-phenylethoxy)isocoumarin 
7-Biotinylamino-4-chloro- 0.2 10-20 2-3 
3-(2-phenylethoxy)isocoumarin 
"Inhibition was measured at O.IM Hepes, O.SM NaCl, pH 7.S buffer, 10% MeiSO and 25' C. Suc-Pbe-Leu-Phe-SBzl 
(0.14 mM) and Z-Oly-Arg-SBzl (0.06 mM) were used to measure chymase and tryptase activity respectively. 
6Inhibition was not time dependent. 
TABLE XV 
Reactivation of Inhibited Chymotrypsin and Rat Granule Chymase by Biotin-
lsocoumarin Derivatives in Buffer and in the Presence of NH20H0 . 
% of Enzyme Activity Reactivated 
Ch;t!!!Ot!:lQsin 
[I) in Rat granule chymase 
Inhibitor (µ.M) bufferb +NH20H +NH20H 
7-(6-Biotinylaminocaproyl)amino-4-chloro- 39 6 50 30-50 
3-(2-phenylethoxy)isocoumarin 78 0 40 
7-Biotinylamino-4-chloro- 39 51 85 100 
3-(2-phenylethoxy)isocoumarin 78 7 79 
"Inhibition was performed at O.IM Hepes, 0.5M NaCl, pH 7.5 buffer, 10% MeiSO and 25' C. Reactivation was carried 
out in the presence of 0.36M of NHzOH, and occurred immediately after the addition of NHzOH. 
~nzyme activity was measured after two days. 
TABLE XVI 
Inhibition Rates of Serine Proteases by 7-substituted-4-chloro-3-bromoalkoxyisocoumarins 
and 7-amino-4-chloro-3-alkox:i:isocoumarins•. 
~1zi[I] {M-ls-1! 
Compounds PP Eb HLF Chymotrypsind Cathepsin G' 
{ll 7-substituted-4-chloro-3-{2-bromoethox:i:!isocoumarin 
7-NH2 1,000 200,ooof 1,160 410 
7-N02 6,330 65,600 98,~ 710 
7-(t-Bu-NH-CO-NH) 6,600 320 56 
7-(isopropyl-NH-CO-NH) 4,470 646.~ 134di 77 
38oh 
7-(Ph-NH-CO-NH) 36 1,200.~ 12 Nii 
7-(Ph-CH2-NH-CO-NH) 3,010 480.~ 890 23o/J 
7-(R-(4ff5)(CH3)CH-NH-CO-NH) 9,900 >440.~ 18oh 77 
9oh 
7-(S-(C6Hs)(CH3)CH-NH-CO-NH) 2,660 >570,~ 440 21o/J 
7-(Naphthyl-NH-CO-NH) 76 390.~ 80 22o/J 
7-((CH3)JC-CH2-CO-NH) 3,650 1,070 240 
7-(Ph-CH2CO-NH) 4,950 480.~ 82,~ 70 
7-(Boc-D-Phe-NH) 30 150 19o/J 
7-(Boc-L-Phe-NH) 50 400 19o/J 
7-(Boc-Ala-Ala-NH) 1,670 230,~ 2,75oh 46 
81oh 
7-(PhNHCSNH) 1,250 >480.~ 39,~ 200 
7-(m-COOH-PhNHCSNH) >240.~ 1,960 320 
7-(p-COOH-PhNHCSNH) >390,~ 1,720 450 
Q!_!. 7-substituted-4-chloro-3:.{3-bromoEro~x:i:!isocoumarin 
7-NH2 10 4,000 790 210 
7-N02 
7-(Ph-NH-CO-NH) 4 13,75oh 180 17o/J 
2,89oh 
7-(Ph-CH2-NH-CO-NH) 13 15,650 440 21o/J 
7-(CH3-CO-NH) 24 24,400 3,980 170 
7-(Ph-CH2-CO-NH) 28 32,350 140.~ 28o/J 
7-(Ph-CH2-CH2CO-NH) 35,65oh 600 NI 
9,87oh 
7-(Boc-D-Phe-NH) 1,480 70 NI 
7-(Boc-L-Phe-NH) 1,320 490 NI 
QIQ. 7-substituted-4-chloro-3:P-bromoisoEro~x:t!isocoumarin 
7-N02 1,060 200.~ 1,660 
7-NH2 62 24,000 320 150 
QY}. 7-amino-4-chloro-3-alkox:i:jsocoumarin 
3-CH3CH2CH20 4.3 390 375 61 
36 
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TABLE XVI-continued 
Inhibition Rates of Serine Proteases by 7-substituted-4-chloro-3-bromoalkoxyisocoumarins 
and 7-amino-4-chloro-3-alkoxyisocoumarins0 • 
Compounds PPEb HLE< Chymotrypsind Cathepsin o• 
0.5 33 140 2.6 
"Inhibition rates were measured in O.IM Hepes, 0.5M NaCl, pH 7.5 buffer, 8-9% Me2SO and at 25' C. Substrates were 
Sue-Ala-Ala-Ala-NA (0.48 mM) for PPE; MeO-Suc-Ala-Ala-Pro-Val-NA (0.24 mM) for HLE; 
Suc-Val-Pro-Phe-NA (0.48 mM) for chymotrypsin and cathepsin G. 
binhibitor concentrations were 0.04-2.0 mM. 
'Inhibitor concentrations were 0.07-710 11M. 
'inhibitor concentrations were 1.7-58 11M. 
'Inhibitor concentrations were 35-710 11M. 
/p,ogress curve method was used according to Tian & Tsou (1982) Biochemistry 21, 1028-1032. 
•Second order rate constant was obtained using equimolar concentration of inhibitor and enzyme. 
~iphasic plot was obtained, and two inhibition rates were shown. 
'NI = No inhibition . 
./percentage of inhibition was obtained after 5 min incubation of inhibitor with enzyme. 
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TABLE XVII TABLE XVIII-continued 
Half-Lives for Dcacylation of Elastascs Inactivated 
by 7-Substituted-4-chloro-3-mcthoxyisocoumarins•. 
Compounds t1 (h) 
20 
Half-Lives for Spontaneous Hydrolysis of lsocoumarin De· 
rivatives in Hepes Buffer", Human Plasma and Rabbit Plasma. 
ll (min) 
7-Substituted HLE PPE 
HOOCCH2CH2CONH 1.5 1.3 
HOOCCH2CH2CH2CONH 1.7 1.5 
o-HOOCC6l14CONH 5.0 17 
CH300CCH2CH2CH2CONH 1.0 1.0 
PhNHCONH >48 >48 
°Enzyme activity was followed after removal of excess inhibitors by centrifugation 
using Amicon centricon·lO microconccntrator. 
TABLE XVIII 
Half-Lives for Spontaneous Hydrolysis of lsocoumarin De· 
rivatives in Hepes Buffer", Human Plasma and Rabbit Plasma. 
tj (min) 
Compounds 
Hepes 
Buffer 
606 
123 
83 
Human Rabbit 
Plasma Plasma 
Compounds 
7-amino-3-(3-isothiureidopropoxy)· 
25 4-chloroisocoumarin 
7-guanidino-3-methoxyisocoumarin 
7-guanidino-3-methoxy-4-
chloroisocoumarin 
7 -guanidino-3-cthoxyisocoumarin 
7-guanidino-3-cthoxy-4-
30 chloroisocoumarin 
7-guanidino-3-(2-phenylethoxy)· 
isocoumarin 
7-guanidino-3-(2·phenylcthoxy)· 
4-chloro-isocoumarin 
isocoumarin 
35 PhCH2NHCONH-CiTPrOIC PhNHCONH-CiTPrOIC 
CH3CONH-CiTPrOIC 
PhCH2CH2CONH-CiTPrOIC 
PhCH2CONH-CiTPrOIC 
PhNHCONH-CiTEtOIC 
Hcpes Human Rabbit 
Buffer Plasma Plasma 
90 165 140 
252 
44 6.7 
136 
39 8.2 4.2 
140 
36 4.5 
148 
148 
68 
66 
61 
108 
3-(3-aminopropoxy)isocoumarin 
3-(3-aminopropoxy)-4-
chloroisocoumarin 
3-(2-isothiureidoethoxy)-4-chloro 
isocoumarin 
3-(3-isothiurcidopropoxy)-4-chloro· 
isocoumarin 
99 0.5 
40 "Conditions wereO.I Hepes, 0.5M NaCl, pH 7.5 and 9% Me2SO at 25" C. Spontane· 
ous hydrolysis rates were measured spectrophotometrica1ly by monitoring the 
decrease in absorbance due to the isocoumarin ring system (wavelength 335-380 
nm) using the first-order rate law. 
TABLE XIX 
Effect of Substituted Isocoumarins on 
PT and APTT of Human, Rabbit and Pig Plasma. 
Compounds 
Control 
3,4-dichloroisocoumarin 
7-guanidino-3-mcthoxy· 
4-chloro-isocoumarin 
7-guanidino-3-cthoxy· 
4-chloro-isocoumarin 
7-guanidino-3-(2-phenyl-
cthoxy )-4-chloroisocoumarin 
3-(3-isothiurcidopropoxy)· 
4-chloro-isocoumarin 
7-amino-3-(3-isothiureido· 
propoxy )-4-chloro-
isocoumarin 
[I] 
(p.M) 
0 
33 
45 
21 
4.3 
15 
21 
31 
53 
75 
107 
124 
27 
31 
2.9 
29 
33 
131 
Human 
Plasma Rabbit Plasma 
PT APTT PT APTT 
(sec) (sec) (sec) (sec) 
12.6 26.7 12.3° 19.0 
12.4 26.6 14.3b 
26.0 
16.5 83.8 
74.8 
14.2° 
22.4 >120 
27.4D 60.S 
17.2b 
31.4 >120 
44.2 
80 >120 
>12ob 
13.0 57.3 
12.3 25.8 
100.8 
19.4 >120 
13.7° 68.6 
62.00 
Pig Plasma 
PT APTT 
(sec) (sec) 
18.6 17.7 
5,324,648 
39 40 
TABLE XIX-continued 
Effect of Substituted lsocoumarins on 
PT and AP1T of Human, Rabbit and Pig Plasma. 
Human 
Plasma Rabbit Plasma Pis Plasma 
[I) PT AP1T PT AP1T PT AP1T 
Compounds (µM) (sec) (sec) (sec) (sec) (sec) (sec) 
PhNHCONH-CiTEtOIC 16 28.5 >120 
32 58.3 
PhCH2NHCONH-CiTEtOIC 32 31.1 >120 
S-C6Hs(CH3)CHNHCONH 32 30.0 >120 
CiTEtOIC 
R-C6ff5(CH3)CHNHCONH- 32 26.2 >120 
CitEtOIC 
"Plasma and inhibitor were incubated at 37• C. for I min., Dade thromboplastin reagent WIS then added. 
bpJasma and inhibitor were incubated at 37• C. for 3 min., Orthobrain thrombopl1Stin reagent WIS then added. 
What is claimed is: 
1. A process for the inhibition of the enzymatic activ-
ity of serine proteases comprising the step of adding to 
a medium containing the protease that amount of inhibi- 20 
tor effective to inhibit said activity having the following 
structure: 
0 
R~~ 
~z 
y 
or a pharmaceutically acceptable salt thereof, wherein 
R is selected from the group consisting ofM-NH-, 
M-0-, AA-NH-, AA-AA-NH-, 
25 
30 
AA-0-, AA-AA-0-, M-AA-NH-, 35 
M-AA-AA-NH-, M-AA-0-, 
M-AA-AA-0-, 
wherein M represents NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X-NH-CS-, 
X-NH-S02-, X-CO-, X-CS-, X-S02-, 40 
X-0-CO-, or X-0-CS-, 
wherein AA represents alanine, valine, leucine, iso-
leucine, proline, methionine, phenylalanine, trypto-
phan, glycine, serine, threonine, cysteine, tyrosine, 
asparagine, glutamine, aspartic acid, glutamic acid, 45 
lysine, arginine, histidine, beta-alanine, norleucine, 
norvaline, phenylglycine, alpha-aminobutyric acid, 
epsilon-aminocaproic acid, citrulline, hydroxypro-
line, ornithine or sarcosine, 
wherein X represents C1-6 alkyl, C1-6 fluoroalkyl, 50 
C1.6 alkyl substituted with K, C1-6 fluoroalkyl sub-
stituted with K, phenyl, phenyl substituted with J, 
phenyl disubstituted with J, phenyl trisubstituted 
with J, naphthyl, naphthyl substituted with J, 
naphthyl disubstituted with J, naphthyl trisubstitu- 55 
ted with J, C1.6 alkyl with an attached phenyl 
group, C1-6 alkyl with two attached phenyl groups, 
Ct-6 alkyl with an attached phenyl group substi-
tuted with J, or C1.6 alkyl with two attached 
phenyl groups substituted with J, 60 
wherein J represents halogen, COOH, OH, CN, N02, 
NH2, C1.6 alkyl, C1.6 alkoxy, C1-6 alkylamine, C1-6 
dialkylamine, C1.6 alkyl-0-CO-, or Ct-6 al-
kyl-0-CO-NH-, 
wherein K represents halogen, COOH; OH, CN, 65 
N02, NH2, C1-6 alkoxy, C1.6 alkylamine, C1-6 dialk-
ylamine, C1.6 alkyl-0-CO-, or C1.6 al-
kyl-0-CO-NH-, 
Z is selected from the group consisting ofC1-6alkoxy 
with an amino group attached to the alkoxy group, 
C1-6 alkoxy with an isothiureido group attached to 
the alkoxy group, C1-6 alkoxy with a guanidino 
group attached to the alkoxy group, C1-6 alkoxy 
with an amidino group attached to the alkoxy 
group, C1.6 alkyl with an amino group attached to 
the alkyl group, C1-6 alkyl with an isothiureido 
group attached to the alkyl group, C1.6alkyl with a 
guanidino group attached to the alkyl group, Ct-6 
alkyl with an amidino group attached to the alkyl 
group, 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH, and methoxy. 
2. A process for the inhibition of the enzymatic activ-
ity of serine proteases comprising the step of adding to 
a medium containing the protease that amount of inhibi-
tor effective to inhibit said activity having the following 
structure: 
0 
R~~ 
~z 
y 
or a pharmaceutically acceptable salt thereof, wherein 
-R is selected from the group consisting ofM-0-, 
M-AA-AA-NH-, M-AA-0-, 
M-AA-AA-0, 
wherein M represents NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X-NH-CS-, 
X-NH-S02-, X-CS-, X-0-CO-, 
X-0-CS-, benzoyl with a J substituent at-
tached to the benzoyl group, phenylsulfonyl with a 
J substituent attached to the phenylsulfonyl group, 
C1-6 alkylsulfonyl with a K substituent attached to 
the C1-6 alkylsulfonyl group, C2-6 alkanoyl with a 
phenyl group attached to the C2-6 alkanoyl group, 
or C2-6 alkanoyl with a phenyl group substituted 
with J attached to the C2.6 alkanoyl group, 
wherein AA represents alanine, valine, leucine, iso-
leucine, proline, methionine, phenylalanine, trypto-
phan, glycine, serine, threonine, cysteine, tyrosine, 
asparagine, glutamine, aspartic acid, glutamic acid, 
lysine, arginine, histidine, beta-alanine, norleucine, 
norvaline, phenylglycine, alpha-aminobutyric acid, 
epsilon-aminocaproic acid, citrulline, hydroxypro-
line, omithine or sarcosine, 
41 
5,324,648 
42 
wherein X represents Ct-6 alkyl, Ct-6 fluoroalkyl, 
Ct-6 alkyl substituted with K, Ct-6 fluoroalkyl sub-
stituted with K, phenyl, phenyl substituted with J, 
phenyl disubstituted with J, phenyl trisubstituted 
with J, naphthyl, naphthyl substituted with J, 5 
naphthyl disubstituted with J, naphthyl trisubstitu-
ted with J, Ct-6 alkyl with an attached phenyl 
group, Ct-6 alkyl with two attached phenyl groups, 
Ct-6 alkyl with an attached phenyl group substi-
tuted with J, or Ct-6 alkyl with two attached 10 
phenyl groups substituted with J, 
wherein J represents halogen, COOH, OH, CN, N02, 
NH2, Ct-6 alkyl, Ct-6 alkoxy, Ct-6 alkylamine, C1-6 
dialkylamine, C1-6 alkyl-0-CO-, or C1-6 alkyl-
0-CO-NH-, 15 
wherein K represents halogen, COOH, OH, CN, 
N02, NH2, C1-6 alkoxy, C1-6 alkylamine, C1-6 dialk-
ylamine, C1-6 alkyl-0-CO-, or Ct-6 alkyl-
0-CO-NH-; 
Z is selected from the group consisting of Ct-6 alkyl, 20 
C1-6 alkoxy, C1-6 alkyl with a phenyl group at-
tached to the C1-6 alkyl, C1-6 alkoxy with a phenyl 
group attached to the C1-6 alkoxy, 
Yis selected from the group consisting ofH, halogen, 
trifluoromethyl, methyl, OH, and methoxy. 25 
3. A process for the inhibition of the enzymatic activ-
ity of serine proteases comprising the step of adding to 
a medium containing the protease that amount of inhibi-
tor effective to inhibit said activity having the following 
strudure: 30 
0 
R~~ 
~z 
y 
35 
or a pharmaceutically acceptable salt thereof, wherein 40 
R is selected from the group consisting of M-NH-, 
M-0-, AA-NH-, AA-AA-NH-, 
AA-0-, AA-AA-0-, M-AA-NH-, 
M-AA-AA-NH-, M-AA-0-, 
M-AA-AA-0-, 45 
wherein M represents NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X-NH-CS-, 
X-NH-S02-, X-CO-, X-CS-, X-S02-, 
X-0-CO-, or X-0-CS-, 
wherein AA represents alanine, valine, leucine, iso- 50 
leucine, praline, methionine, phenylalanine, trypto-
phan, glycine, serine, threonine, cysteine, tyrosine, 
asparagine, glutamine, aspartic acid, glutamic acid, 
lysine, arginine, histidine, beta-alanine, norleucine, 
norvaline, phenylglycine, alpha-arninobutyric acid, 55 
epsilon-aminocaproic acid, citrulline, hydroxypro-
line, ornithine or sarcosine, 
wherein X represents C1-6 alkyl, Ct-6 fluoroalkyl, 
C1-6 alkyl substituted with K, C1-6 fluoroalkyl sub-
stituted with K, phenyl, phenyl substituted with J, 60 
phenyl disubstituted with J, phenyl trisubstituted 
with J, naphthyl, naphthyl substituted with J, 
naphthyl disubstituted with J, naphthyl trisubstitu-
ted with J, C1-6 alkyl with an attached phenyl 
group, C1-6alkyl with two attached phenyl groups, 65 
C1-6 alkyl with an attached phenyl group substi-
tuted with J, or C1-6 alkyl with two attached 
phenyl groups substituted with J, 
wherein J represents halogen, COOH, OH, CN, N02, 
NH2, Ct-6 alkyl, Ct-6 alkoxy, Ct-6 alkylarnine, C1-6 
dialkylamine, C1-6 alkyl-0-CO-, or C1.6 alkyl-
0-CO-NH-, 
wherein K represents halogen, COOH, OH, CN, 
N02, NH2, C1-6alkoxy, C1-6alkylamine, C1-6dialk-
ylamine, C1-6 alkyl-0-CO-, or C1-6 alkyl-
0-CO-NH-, 
Z is selected from the group consisting ofC1-6alkoxy 
with a bromine attached to the alkoxy group, C1-6 
alkyl with a bromine attached to the alk.Yl group, 
C1-6 alkoxy with an attached C1-6 alkoxy group 
substituted with Q, 
wherein Q represents H, or C1-6 alkoxy, 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH, and methoxy. 
4. A process for the inhibition of the enzymatic activ-
ity of serine proteases comprising the step of adding to 
a medium containing the protease that amount of inhibi-
tor effective to inhibit said activity having the following 
structure: 
0 
R~~ 
~z 
y 
or a pharmaceutically acceptable salt thereof, wherein 
R is Ct-6 alkyl with an isothiureido group of the for-
mula -S-C(-NH)NH2 attached to the alkyl 
group, 
Z is selected from the group consisting of H, halogen, 
C1-6 alkyl, C1-6 fluorinated alkyl, C1-6 alkyl substi-
tuted with K, Ct-6 fluorinated alkyl substituted 
with K, C1.6 alkoxy, Ct-6 fluorinated alkoxy, Ct-6 
alkoxy substituted with K, Ct-6 fluorinated alkoxy 
substituted with K, C1-6 alkyl with a phenyl group 
attached to the alkyl group, C1-6 alkoxy with a 
phenyl group attached to the alkoxy group, C1-6 
alkyl with an attached phenyl group substituted 
with J, Ct-6 alkyl with an attached phenyl group 
disubstituted with J, C1-6 alkoxy with an attached 
phenyl group substituted with J, C1-6 alkoxy with 
an attached phenyl group disubstituted with J, 
· wherein J represents halogen, COOH, OH, CN, N02, 
NH2, Ct-6 alkyl, Ct-6 alkoxy, Ct-6 alkylamine, Ct-6 
dialkylamine, Ct-6 alkyl-0-CO-, Ct-6 alkyl-
0-CO-NH-, or Ct-6 alkyl-S-, 
wherein K represents halogen, COOH, OH, CN, 
N02, NH2, C1-6alkoxy, C1-6alkylamine, Ct-6dialk-
ylamine, C1-6 alkyl-0-CO-, Ct-6 alkyl-
0-CO-NH-, C1-6 alkyl-S-, or tosylamino, 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH, and methoxy. 
S. A process for the inhibition of the enzymatic activ-
ity of serine proteases comprising the step of adding to 
a medium containing the protease that amount of inhibi-
tor effective to inhibit said activity having the following 
structure: 
43 
5,324,648 
0 
R~~ 
~z 
y 
5 
or a pharmaceutically acceptable salt thereof, wherein 10 
R is selected from the group consisting of -N-
H-C( NH)NH2, -C( NH)NH2, C1..i; alkyl 
with an amino group attached to the C1-6 alkyl, 
C1-6 alkyl with an isothiureido group attached to 
the C1..i; alkyl, 15 . 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
44 
Z is selected from the group consisting of C1..i; alkoxy 
with an amino group attached to the alkoxy group, 
C1-6 alkoxy with an isothiureido group attached to 
the alkoxy group, C1-6 alkoxy with a guanidino 
group attached to the alkoxy group, C1-6 alkoxy 
with an amidino group attached to the alkoxy 
group, C1-6 alkyl with an amino group attached to 
the alkyl group, C1-6 alkyl with an isothiureido 
group attached to the alkyl group, C1..i; alkyl with a 
guanidino group attached to the alkyl group, C1-6 
alkyl with an amidino group attached to the alkyl 
group, 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH, and methoxy. 
• • • • • 
